<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" id="wjs12484" xml:lang="en" article-type="research-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">World J Surg</journal-id><journal-id journal-id-type="iso-abbrev">World J Surg</journal-id><journal-id journal-id-type="pmc-domain-id">379</journal-id><journal-id journal-id-type="pmc-domain">blackwellopen</journal-id><journal-id journal-id-type="publisher-id">WJS</journal-id><journal-title-group><journal-title>World Journal of Surgery</journal-title></journal-title-group><issn pub-type="ppub">0364-2313</issn><issn pub-type="epub">1432-2323</issn><custom-meta-group><custom-meta><meta-name>pmc-is-collection-domain</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-collection-title</meta-name><meta-value>Wiley Open Access Collection</meta-value></custom-meta></custom-meta-group></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC11903251</article-id><article-id pub-id-type="pmcid-ver">PMC11903251.1</article-id><article-id pub-id-type="pmcaid">11903251</article-id><article-id pub-id-type="pmcaiid">11903251</article-id><article-id pub-id-type="pmid">39788883</article-id><article-id pub-id-type="doi">10.1002/wjs.12484</article-id><article-id pub-id-type="publisher-id">WJS12484</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="overline"><subject>Original Research</subject></subj-group><subj-group subj-group-type="heading"><subject>Perioperative Care</subject></subj-group></article-categories><title-group><article-title>Impact of Preoperative Glucagon&#8208;Like Peptide&#8208;1 Receptor Agonist on Outcomes Following Major Surgery</article-title></title-group><contrib-group><contrib id="wjs12484-cr-0001" contrib-type="author"><name name-style="western"><surname>Rashid</surname><given-names initials="Z">Zayed</given-names></name><xref rid="wjs12484-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="wjs12484-cr-0002" contrib-type="author"><name name-style="western"><surname>Woldesenbet</surname><given-names initials="S">Selamawit</given-names></name><xref rid="wjs12484-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="wjs12484-cr-0003" contrib-type="author"><name name-style="western"><surname>Khalil</surname><given-names initials="M">Mujtaba</given-names></name><xref rid="wjs12484-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="wjs12484-cr-0004" contrib-type="author"><name name-style="western"><surname>Altaf</surname><given-names initials="A">Abdullah</given-names></name><xref rid="wjs12484-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="wjs12484-cr-0005" contrib-type="author"><name name-style="western"><surname>Kawashima</surname><given-names initials="J">Jun</given-names></name><xref rid="wjs12484-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="wjs12484-cr-0006" contrib-type="author"><name name-style="western"><surname>Mumtaz</surname><given-names initials="K">Khalid</given-names></name><xref rid="wjs12484-aff-0002" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib id="wjs12484-cr-0007" contrib-type="author" corresp="yes"><name name-style="western"><surname>Pawlik</surname><given-names initials="TM">Timothy M.</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-7994-9870</contrib-id><xref rid="wjs12484-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><address><email>tim.Pawlik@osumc.edu</email></address></contrib></contrib-group><aff id="wjs12484-aff-0001">
<label>
<sup>1</sup>
</label>
<named-content content-type="organisation-division">Department of Surgery</named-content>
<institution>The Ohio State University Wexner Medical Center and James Comprehensive Cancer Center</institution>
<city>Columbus</city>
<named-content content-type="country-part">Ohio</named-content>
<country country="US">USA</country>
</aff><aff id="wjs12484-aff-0002">
<label>
<sup>2</sup>
</label>
<named-content content-type="organisation-division">Department of Internal Medicine</named-content>
<named-content content-type="organisation-division">Division of Palliative Care</named-content>
<institution>The Ohio State University Wexner Medical Center and James Comprehensive Cancer Center</institution>
<city>Columbus</city>
<named-content content-type="country-part">Ohio</named-content>
<country country="US">USA</country>
</aff><author-notes><corresp id="correspondenceTo"><label>*</label><bold>Correspondence:</bold> Timothy M. Pawlik<break/>
(<email>tim.Pawlik@osumc.edu</email>)<break/></corresp></author-notes><pub-date pub-type="epub"><day>09</day><month>1</month><year>2025</year></pub-date><pub-date pub-type="ppub"><month>3</month><year>2025</year></pub-date><volume>49</volume><issue seq="230">3</issue><issue-id pub-id-type="pmc-issue-id">484122</issue-id><issue-id pub-id-type="doi">10.1002/wjs.v49.3</issue-id><fpage>698</fpage><lpage>707</lpage><history><date date-type="rev-recd"><day>14</day><month>12</month><year>2024</year></date><date date-type="received"><day>12</day><month>10</month><year>2024</year></date><date date-type="accepted"><day>29</day><month>12</month><year>2024</year></date></history><pub-history><event event-type="pmc-release"><date><day>13</day><month>03</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>14</day><month>03</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-03-14 00:25:18.907"><day>14</day><month>03</month><year>2025</year></date></event></pub-history><permissions><copyright-statement content-type="article-copyright">&#169; 2025 The Author(s). <italic toggle="yes">World Journal of Surgery</italic> published by John Wiley &amp; Sons Ltd on behalf of International Society of Surgery/Soci&#233;t&#233; Internationale de Chirurgie (ISS/SIC).</copyright-statement><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open access article under the terms of the <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link> License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="WJS-49-698.pdf"/><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pdf" xlink:href="file:WJS-49-698.pdf"/><abstract><title>ABSTRACT</title><sec id="wjs12484-sec-0001"><title>Background</title><p>Glucagon&#8208;like peptide&#8208;1 receptor agonists (GLP&#8208;1RA) are increasingly being used for the management of diabetes mellitus and obesity. We sought to define the impact of preoperative GLP&#8208;1RA use on outcomes following major surgical procedures.</p></sec><sec id="wjs12484-sec-0002"><title>Methods</title><p>Patients who underwent a major surgical procedure between 2013 and 2021 were identified using the IBM MarketScan database. Patients who took GLP&#8208;1RA within a year before surgery were categorized as &#8220;exposed.&#8221; After propensity score matching (PSM), multivariable regression analysis was used to define the association of GLP&#8208;1RA exposure with postoperative complications.</p></sec><sec id="wjs12484-sec-0003"><title>Results</title><p>Among 138,980 patients (coronary artery bypass graft: <italic toggle="yes">n</italic>&#160;=&#160;39,516, 28.4%; pneumonectomy: <italic toggle="yes">n</italic>&#160;=&#160;4,881, 3.5%; abdominal aortic aneurysm repair: 4,459, 3.3%; pancreatectomy: <italic toggle="yes">n</italic>&#160;=&#160;15,873, 11.4%; and colectomy: <italic toggle="yes">n</italic>&#160;=&#160;74,251, 53.4%), most individuals were male (<italic toggle="yes">n</italic>&#160;=&#160;80,871, 58.2%) with a median age of 58 (IQR 53&#8211;61) years. 2944 (2.2%) individuals had GLP&#8208;1RA exposure before surgery. Overall incidence of complications was 36.5% (<italic toggle="yes">n</italic>&#160;=&#160;50,724); complications included sepsis (<italic toggle="yes">n</italic>&#160;=&#160;6,385, 4.6%), surgical site infections (<italic toggle="yes">n</italic>&#160;=&#160;7,431, 5.3%), thromboembolism (<italic toggle="yes">n</italic>&#160;=&#160;3,609, 2.6%), pneumonia (<italic toggle="yes">n</italic>&#160;=&#160;4,783, 3.4%), renal (<italic toggle="yes">n</italic>&#160;=&#160;9,017, 6.5%), or cardiopulmonary failure (<italic toggle="yes">n</italic>&#160;=&#160;26,661, 19.2%). On unmatched analysis, patients on GLP&#8208;1RA had a higher risk of complications (no GLP&#8208;1RA: 36.3% vs. GLP&#8208;1RA: 44.5% <italic toggle="yes">p</italic>&#160;&lt;&#160;0.001); however, after PSM to account for measured confounders, GLP&#8208;1RA exposure was not associated with the odds of surgical complications (OR 0.99 95% CI 0.91&#8211;1.08; <italic toggle="yes">p</italic>&#160;&gt;&#160;0.05). Among patients using GLP&#8208;1RA during the 2 weeks before surgery (<italic toggle="yes">n</italic>&#160;=&#160;522, 17.7%), there was no association of GLP&#8208;1RA with risk of complications (nonrecent GLP&#8208;1RA: 44.7% vs. recent GLP&#8208;1RA: 44.1%; <italic toggle="yes">p</italic>&#160;=&#160;0.992).</p></sec><sec id="wjs12484-sec-0004"><title>Conclusions</title><p>GLP&#8208;1RA use was not associated with an increased risk of complications following major surgical procedures.</p></sec></abstract><abstract abstract-type="graphical"><p>GLP&#8208;1RA use was not associated with an increased risk of complications following major surgical procedures (coronary artery bypass graft, pneumonectomy, abdominal aortic aneurysm repair, pancreatectomy, and colectomy) even among patients who continued the medication up until the time of surgery.<boxed-text position="anchor" content-type="graphic" orientation="portrait"><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-1" orientation="portrait" xlink:href="WJS-49-698-g002.jpg"/></boxed-text>
</p></abstract><kwd-group><kwd id="wjs12484-kwd-0001">GLP&#8208;1RA</kwd><kwd id="wjs12484-kwd-0002">ileus</kwd><kwd id="wjs12484-kwd-0003">major surgical procedures</kwd><kwd id="wjs12484-kwd-0004">MarketScan</kwd><kwd id="wjs12484-kwd-0005">surgical complications</kwd></kwd-group><counts><fig-count count="4"/><table-count count="3"/><page-count count="10"/><word-count count="6416"/></counts><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>source-schema-version-number</meta-name><meta-value>2.0</meta-value></custom-meta><custom-meta><meta-name>cover-date</meta-name><meta-value>March 2025</meta-value></custom-meta><custom-meta><meta-name>details-of-publishers-convertor</meta-name><meta-value>Converter:WILEY_ML3GV2_TO_JATSPMC version:6.5.4 mode:remove_FC converted:12.03.2025</meta-value></custom-meta></custom-meta-group></article-meta><notes><fn-group><fn id="wjs12484-note-0001"><p>
<bold>Funding:</bold> The authors received no specific funding for this work.</p></fn></fn-group></notes></front><body id="wjs12484-body-0001"><sec id="wjs12484-sec-0010"><label>1</label><title>Introduction</title><p>Glucagon&#8208;like peptide&#8208;1 receptor agonists (GLP&#8208;1RA) are increasingly being used for the management of diabetes mellitus (DM) and obesity [<xref rid="wjs12484-bib-0001" ref-type="bibr">1</xref>, <xref rid="wjs12484-bib-0002" ref-type="bibr">2</xref>, <xref rid="wjs12484-bib-0003" ref-type="bibr">3</xref>]. The increased utilization can be attributed to the beneficial effects on weight loss as well as cardiovascular, renal, and liver function [<xref rid="wjs12484-bib-0001" ref-type="bibr">1</xref>, <xref rid="wjs12484-bib-0004" ref-type="bibr">4</xref>]. However, these favorable outcomes can come at the expense of adverse effects, particularly gastrointestinal issues such as delayed gastric emptying [<xref rid="wjs12484-bib-0005" ref-type="bibr">5</xref>]. In fact, up to 70% of individuals using GLP&#8208;1RA may experience some type of adverse effect [<xref rid="wjs12484-bib-0005" ref-type="bibr">5</xref>]. These undesirable effects can be particularly problematic among surgical patients, who are already susceptible to complications such as decreased gut motility, hypoglycemia, and aspiration [<xref rid="wjs12484-bib-0003" ref-type="bibr">3</xref>]. Whether certain antidiabetic drugs, such as GLP&#8208;1RA, contribute to the burden of surgical morbidity remains a topic of debate [<xref rid="wjs12484-bib-0003" ref-type="bibr">3</xref>, <xref rid="wjs12484-bib-0006" ref-type="bibr">6</xref>]. In turn, there has been a growing interest in the evaluation of GLP&#8208;1RA's impact on patients in the perioperative period [<xref rid="wjs12484-bib-0007" ref-type="bibr">7</xref>].</p><p>Recent studies have noted that GLP&#8208;1RA medications, traditionally associated with glucose regulation, can affect different physiological pathways [<xref rid="wjs12484-bib-0008" ref-type="bibr">8</xref>, <xref rid="wjs12484-bib-0009" ref-type="bibr">9</xref>]. For example, the nonglycemic benefits of GLP&#8208;1RA include weight loss, improved blood pressure regulation, enhanced cardiac function, and better management of dyslipidemia [<xref rid="wjs12484-bib-0001" ref-type="bibr">1</xref>, <xref rid="wjs12484-bib-0008" ref-type="bibr">8</xref>, <xref rid="wjs12484-bib-0009" ref-type="bibr">9</xref>]. Therefore, the impact of GLP&#8208;1RA drugs on medical comorbidities may indirectly benefit patients who are undergoing surgery [<xref rid="wjs12484-bib-0010" ref-type="bibr">10</xref>, <xref rid="wjs12484-bib-0011" ref-type="bibr">11</xref>]. To this point, Buddhiraju et&#160;al. reported that GLP&#8208;1RA use before elective total knee and hip replacement was associated with lower odds of postsurgical infection and readmission [<xref rid="wjs12484-bib-0006" ref-type="bibr">6</xref>]. In a separate study, Dixit et&#160;al. reported no difference in respiratory complications relative to GLP&#8208;1RA exposure among patients undergoing emergency gynecologic or orthopedic procedures [<xref rid="wjs12484-bib-0007" ref-type="bibr">7</xref>]. In fact, some data have suggested that discontinuation of these medications during the perioperative period may worsen glycemic control and hinder recovery from surgery [<xref rid="wjs12484-bib-0012" ref-type="bibr">12</xref>, <xref rid="wjs12484-bib-0013" ref-type="bibr">13</xref>].</p><p>Current guidelines from the American Society of Anesthesiologists (ASA) recommend stopping GLP&#8208;1RA medications prior to surgery [<xref rid="wjs12484-bib-0014" ref-type="bibr">14</xref>]. Withholding these newer agents of antiglycemic agents can lead to unnecessary delays in care and logistical challenges [<xref rid="wjs12484-bib-0007" ref-type="bibr">7</xref>]. Given the limited data on the risks versus benefits of using GLP&#8208;1RA in the perioperative period, we sought to define the impact of GLP&#8208;1RA use on complications among patients undergoing a major surgical procedure.</p></sec><sec id="wjs12484-sec-0020"><label>2</label><title>Material and Methods</title><p>Patients who underwent a major surgical procedure between 2013 and 2021 were identified from the commercial IBM MarketScan database (Supplementary eMethods in Supporting Information&#160;<xref rid="wjs12484-sup-0001" ref-type="supplementary-material">S1</xref>) [<xref rid="wjs12484-bib-0015" ref-type="bibr">15</xref>]. The International Classification of Diseases, ninth and tenth editions (ICD&#8208;9/10) codes were utilized to identify patients under 65&#160;years of age who underwent coronary artery bypass graft (CABG), pneumonectomy, abdominal aortic aneurysm repair (AAA), pancreatectomy, and colectomy. National drug codes were used to identify patients who had at least one claim for GLP&#8208;1RA therapy (Semaglutide, Albiglutide, Liraglutide, Dulaglutide, Lixisenatide, or Exenatide) from 1&#160;year up to 15&#160;days before the index surgery (i.e., &#8220;exposed&#8221;); the remaining cohort was designated as the non&#8208;GLP&#8208;1RA group (i.e., &#8220;non&#8208;exposed&#8221;). Patients who had noncontinuous enrollment in the benefit plan for 1&#160;year before and 90 days after surgery, had <italic toggle="yes">de novo</italic> GLP&#8208;1RA initiation within 2&#160;weeks before surgery or who took GLP&#8208;1RA within 90 days after surgery were excluded (Figure&#160;<xref rid="wjs12484-fig-0001" ref-type="fig">1</xref>). Similarly, patients who underwent an additional surgical procedure unrelated to the index procedure of interest were excluded from the study [<xref rid="wjs12484-bib-0016" ref-type="bibr">16</xref>]. The need for informed consent for deidentified data was waived by the institutional review board (IRB) of the Ohio State University. This study followed the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) reporting guidelines.</p><fig position="float" fig-type="FIGURE" id="wjs12484-fig-0001" orientation="portrait"><label>FIGURE 1</label><caption><p>The flowchart depicting the number of patients included according to the study criteria.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-3" orientation="portrait" xlink:href="WJS-49-698-g004.jpg"/></fig><sec id="wjs12484-sec-0030"><label>2.1</label><title>Variables, Exposure, and Outcome</title><p>Variables of interest included patient age, sex, benefit plan type, employment status, Charlson Comorbidity Index (CCI), US census region (Northeast, Northcentral, South, and West), rurality (metropolitan vs. nonmetropolitan), claim&#8208;based frailty index, and baseline concurrent medical conditions (Table&#160;<xref rid="wjs12484-tbl-0001" ref-type="table">1</xref>). Patients were identified as residing in metropolitan or nonmetropolitan areas using the United States Department of Agriculture Rural&#8208;Urban Continuum Codes [<xref rid="wjs12484-bib-0017" ref-type="bibr">17</xref>, <xref rid="wjs12484-bib-0018" ref-type="bibr">18</xref>]. Patient sex was defined as male or female, based on sex assigned at birth [<xref rid="wjs12484-bib-0019" ref-type="bibr">19</xref>]. Patient employment status was categorized as actively employed, retired, and &#8220;Other.&#8221; The &#8220;Other&#8221; category included individuals with long&#8208;term disabilities, COBRA continuers, and dependents. Similarly, using the claim&#8208;based frailty index, patients were categorized as nonfrail, prefrail, and frail [<xref rid="wjs12484-bib-0020" ref-type="bibr">20</xref>]. Additionally, the CCI classified patients based on the severity of their preoperative comorbidities using a cutoff value of 2 as described in earlier studies [<xref rid="wjs12484-bib-0021" ref-type="bibr">21</xref>, <xref rid="wjs12484-bib-0022" ref-type="bibr">22</xref>]. Furthermore, the ICD 9/10 codes identified any baseline comorbid conditions related to the cardiovascular, central nervous, and gastrointestinal systems (Table&#160;<xref rid="wjs12484-tbl-0002" ref-type="table">2</xref>) [<xref rid="wjs12484-bib-0001" ref-type="bibr">1</xref>].</p><table-wrap position="float" id="wjs12484-tbl-0001" content-type="TABLE" orientation="portrait"><label>TABLE 1</label><caption><p>Baseline characteristics of patients who underwent complex surgical procedures relative to glucagon&#8208;like peptide&#8208;1 receptor agonists initiation.</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><thead valign="bottom"><tr><th rowspan="2" style="border-bottom:solid 1px #000000" align="left" valign="bottom" colspan="1">Patient characteristics</th><th align="center" valign="bottom" rowspan="1" colspan="1"/><th style="border-bottom:solid 1px #000000" colspan="3" align="center" valign="bottom" rowspan="1">Unmatched</th><th style="border-bottom:solid 1px #000000" colspan="3" align="center" valign="bottom" rowspan="1">Matched</th></tr><tr style="border-bottom:solid 1px #000000"><th align="center" valign="bottom" rowspan="1" colspan="1">Total <italic toggle="yes">N</italic>&#160;=&#160;138,980</th><th align="center" valign="bottom" rowspan="1" colspan="1">GLP&#8208;1RA <italic toggle="yes">N</italic>&#160;=&#160;2944</th><th align="center" valign="bottom" rowspan="1" colspan="1">Non GLP&#8208;1RA <italic toggle="yes">N</italic>&#160;=&#160;136,036</th><th align="center" valign="bottom" rowspan="1" colspan="1">
<italic toggle="yes">p</italic>&#8208;value</th><th align="center" valign="bottom" rowspan="1" colspan="1">GLP&#8208;1RA <italic toggle="yes">N</italic>&#160;=&#160;2943</th><th align="center" valign="bottom" rowspan="1" colspan="1">Non GLP&#8208;1RA <italic toggle="yes">N</italic>&#160;=&#160;5863</th><th align="center" valign="bottom" rowspan="1" colspan="1">
<italic toggle="yes">p</italic>&#8208;value</th></tr></thead><tbody valign="top"><tr><td colspan="8" align="left" valign="top" rowspan="1">Age, years</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Mean (SD)</td><td align="center" valign="top" rowspan="1" colspan="1">54.9&#160;&#177;&#160;7.9</td><td align="center" valign="top" rowspan="1" colspan="1">56.4&#160;&#177;&#160;6.2</td><td align="center" valign="top" rowspan="1" colspan="1">53.4&#160;&#177;&#160;9.5</td><td align="center" valign="top" rowspan="1" colspan="1">&lt;&#160;0.001</td><td align="center" valign="top" rowspan="1" colspan="1">56.4&#160;&#177;&#160;6.2</td><td align="center" valign="top" rowspan="1" colspan="1">56.4&#160;&#177;&#160;6.6</td><td align="center" valign="top" rowspan="1" colspan="1">0.808</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Median (IQR)</td><td align="center" valign="top" rowspan="1" colspan="1">58 (53&#8211;61)</td><td align="center" valign="top" rowspan="1" colspan="1">56 (49&#8211;60)</td><td align="center" valign="top" rowspan="1" colspan="1">58 (53&#8211;61)</td><td align="center" valign="top" rowspan="1" colspan="1">&lt;&#160;0.001</td><td align="center" valign="top" rowspan="1" colspan="1">58 (53&#8211;61)</td><td align="center" valign="top" rowspan="1" colspan="1">58 (53&#8211;61)</td><td align="center" valign="top" rowspan="1" colspan="1">0.808</td></tr><tr><td colspan="8" align="left" valign="top" rowspan="1">Sex</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Male</td><td align="center" valign="top" rowspan="1" colspan="1">80,871 (58.2%)</td><td align="center" valign="top" rowspan="1" colspan="1">1792 (60.9)</td><td align="center" valign="top" rowspan="1" colspan="1">79,079 (58.1)</td><td align="center" valign="top" rowspan="1" colspan="1">0.003</td><td align="center" valign="top" rowspan="1" colspan="1">1151 (39.1)</td><td align="center" valign="top" rowspan="1" colspan="1">2326 (39.7)</td><td align="center" valign="top" rowspan="1" colspan="1">0.610</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Female</td><td align="center" valign="top" rowspan="1" colspan="1">58,109 (41.8%)</td><td align="center" valign="top" rowspan="1" colspan="1">1152 (39.1)</td><td align="center" valign="top" rowspan="1" colspan="1">56,957 (41.9)</td><td align="center" valign="top" rowspan="1" colspan="1">0.003</td><td align="center" valign="top" rowspan="1" colspan="1">1792 (60.9)</td><td align="center" valign="top" rowspan="1" colspan="1">3537 (60.3)</td><td align="center" valign="top" rowspan="1" colspan="1">0.610</td></tr><tr><td colspan="8" align="left" valign="top" rowspan="1">Region</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Northeast</td><td align="center" valign="top" rowspan="1" colspan="1">23,463 (16.9%)</td><td align="center" valign="top" rowspan="1" colspan="1">373 (12.7)</td><td align="center" valign="top" rowspan="1" colspan="1">23,090 (17.0)</td><td align="center" valign="top" rowspan="1" colspan="1">&lt;&#160;0.001</td><td align="center" valign="top" rowspan="1" colspan="1">373 (12.7)</td><td align="center" valign="top" rowspan="1" colspan="1">727 (12.4)</td><td align="center" valign="top" rowspan="1" colspan="1">0.780</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">North central</td><td align="center" valign="top" rowspan="1" colspan="1">30,586 (22.0%)</td><td align="center" valign="top" rowspan="1" colspan="1">574 (19.5)</td><td align="center" valign="top" rowspan="1" colspan="1">30,012 (22.1)</td><td align="center" valign="top" rowspan="1" colspan="1">&lt;&#160;0.001</td><td align="center" valign="top" rowspan="1" colspan="1">574 (19.5)</td><td align="center" valign="top" rowspan="1" colspan="1">1103 (18.8)</td><td align="center" valign="top" rowspan="1" colspan="1">0.780</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">South</td><td align="center" valign="top" rowspan="1" colspan="1">66,000 (47.5%)</td><td align="center" valign="top" rowspan="1" colspan="1">1713 (58.2)</td><td align="center" valign="top" rowspan="1" colspan="1">64,287 (47.3)</td><td align="center" valign="top" rowspan="1" colspan="1">&lt;&#160;0.001</td><td align="center" valign="top" rowspan="1" colspan="1">1712 (58.2)</td><td align="center" valign="top" rowspan="1" colspan="1">3463 (59.1)</td><td align="center" valign="top" rowspan="1" colspan="1">0.780</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">West</td><td align="center" valign="top" rowspan="1" colspan="1">17,518 (12.6%)</td><td align="center" valign="top" rowspan="1" colspan="1">271 (9.2)</td><td align="center" valign="top" rowspan="1" colspan="1">17,247 (12.7)</td><td align="center" valign="top" rowspan="1" colspan="1">&lt;&#160;0.001</td><td align="center" valign="top" rowspan="1" colspan="1">271 (9.2)</td><td align="center" valign="top" rowspan="1" colspan="1">535 (9.1)</td><td align="center" valign="top" rowspan="1" colspan="1">0.780</td></tr><tr><td colspan="8" align="left" valign="top" rowspan="1">Type of health insurance</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">PPO</td><td align="center" valign="top" rowspan="1" colspan="1">79,839 (57.4%)</td><td align="center" valign="top" rowspan="1" colspan="1">1695 (57.6)</td><td align="center" valign="top" rowspan="1" colspan="1">78,144 (57.4)</td><td align="center" valign="top" rowspan="1" colspan="1">0.075</td><td align="center" valign="top" rowspan="1" colspan="1">1694 (57.6)</td><td align="center" valign="top" rowspan="1" colspan="1">3400 (58.0)</td><td align="center" valign="top" rowspan="1" colspan="1">0.961</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">HMO</td><td align="center" valign="top" rowspan="1" colspan="1">15,318 (11.0%)</td><td align="center" valign="top" rowspan="1" colspan="1">280 (9.5)</td><td align="center" valign="top" rowspan="1" colspan="1">15,038 (11.1)</td><td align="center" valign="top" rowspan="1" colspan="1">0.075</td><td align="center" valign="top" rowspan="1" colspan="1">280 (9.5)</td><td align="center" valign="top" rowspan="1" colspan="1">535 (9.1)</td><td align="center" valign="top" rowspan="1" colspan="1">0.961</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Comprehensive</td><td align="center" valign="top" rowspan="1" colspan="1">5694 (4.1%)</td><td align="center" valign="top" rowspan="1" colspan="1">120 (4.1)</td><td align="center" valign="top" rowspan="1" colspan="1">5574 (4.1)</td><td align="center" valign="top" rowspan="1" colspan="1">0.075</td><td align="center" valign="top" rowspan="1" colspan="1">120 (4.1)</td><td align="center" valign="top" rowspan="1" colspan="1">228 (3.9)</td><td align="center" valign="top" rowspan="1" colspan="1">0.961</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">POS</td><td align="center" valign="top" rowspan="1" colspan="1">9788 (7.0%)</td><td align="center" valign="top" rowspan="1" colspan="1">214 (7.3)</td><td align="center" valign="top" rowspan="1" colspan="1">9574 (7.0)</td><td align="center" valign="top" rowspan="1" colspan="1">0.075</td><td align="center" valign="top" rowspan="1" colspan="1">214 (7.3)</td><td align="center" valign="top" rowspan="1" colspan="1">435 (7.4)</td><td align="center" valign="top" rowspan="1" colspan="1">0.961</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Other<xref rid="wjs12484-note-0003" ref-type="table-fn">
<sup>a</sup>
</xref>
</td><td align="center" valign="top" rowspan="1" colspan="1">28,341 (20.4%)</td><td align="center" valign="top" rowspan="1" colspan="1">635 (21.6)</td><td align="center" valign="top" rowspan="1" colspan="1">27,706 (20.4)</td><td align="center" valign="top" rowspan="1" colspan="1">0.075</td><td align="center" valign="top" rowspan="1" colspan="1">635 (21.6)</td><td align="center" valign="top" rowspan="1" colspan="1">1265 (21.6)</td><td align="center" valign="top" rowspan="1" colspan="1">0.961</td></tr><tr><td colspan="8" align="left" valign="top" rowspan="1">Employment status</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Other</td><td align="center" valign="top" rowspan="1" colspan="1">73,736 (53.1%)</td><td align="center" valign="top" rowspan="1" colspan="1">1738 (59.0)</td><td align="center" valign="top" rowspan="1" colspan="1">71,998 (52.9)</td><td align="center" valign="top" rowspan="1" colspan="1">&lt;&#160;0.001</td><td align="center" valign="top" rowspan="1" colspan="1">1735 (59.0)</td><td align="center" valign="top" rowspan="1" colspan="1">3462 (59.0)</td><td align="center" valign="top" rowspan="1" colspan="1">0.999</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Full/part&#8208;time</td><td align="center" valign="top" rowspan="1" colspan="1">16,358 (11.8%)</td><td align="center" valign="top" rowspan="1" colspan="1">389 (13.2)</td><td align="center" valign="top" rowspan="1" colspan="1">15,969 (11.7)</td><td align="center" valign="top" rowspan="1" colspan="1">&lt;&#160;0.001</td><td align="center" valign="top" rowspan="1" colspan="1">389 (13.2)</td><td align="center" valign="top" rowspan="1" colspan="1">775 (13.2)</td><td align="center" valign="top" rowspan="1" colspan="1">0.999</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Retired</td><td align="center" valign="top" rowspan="1" colspan="1">48,886 (35.2%)</td><td align="center" valign="top" rowspan="1" colspan="1">817 (27.8)</td><td align="center" valign="top" rowspan="1" colspan="1">48,069 (35.3)</td><td align="center" valign="top" rowspan="1" colspan="1">&lt;&#160;0.001</td><td align="center" valign="top" rowspan="1" colspan="1">817 (27.8)</td><td align="center" valign="top" rowspan="1" colspan="1">1626 (27.7)</td><td align="center" valign="top" rowspan="1" colspan="1">0.999</td></tr><tr><td colspan="8" align="left" valign="top" rowspan="1">CCI</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">&#8804; 2</td><td align="center" valign="top" rowspan="1" colspan="1">81,675 (58.8%)</td><td align="center" valign="top" rowspan="1" colspan="1">1278 (43.4)</td><td align="center" valign="top" rowspan="1" colspan="1">80,397 (59.1)</td><td align="center" valign="top" rowspan="1" colspan="1">&lt;&#160;0.001</td><td align="center" valign="top" rowspan="1" colspan="1">1278 (43.4)</td><td align="center" valign="top" rowspan="1" colspan="1">2557 (43.6)</td><td align="center" valign="top" rowspan="1" colspan="1">0.867</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">&gt; 2</td><td align="center" valign="top" rowspan="1" colspan="1">57,305 (41.2%)</td><td align="center" valign="top" rowspan="1" colspan="1">1666 (56.6)</td><td align="center" valign="top" rowspan="1" colspan="1">55,639 (40.9)</td><td align="center" valign="top" rowspan="1" colspan="1">&lt;&#160;0.001</td><td align="center" valign="top" rowspan="1" colspan="1">1665 (56.6)</td><td align="center" valign="top" rowspan="1" colspan="1">3306 (56.4)</td><td align="center" valign="top" rowspan="1" colspan="1">0.867</td></tr><tr><td colspan="8" align="left" valign="top" rowspan="1">Claim&#8208;based frailty index</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Nonfrail</td><td align="center" valign="top" rowspan="1" colspan="1">90,213 (64.9%)</td><td align="center" valign="top" rowspan="1" colspan="1">1044 (35.5)</td><td align="center" valign="top" rowspan="1" colspan="1">89,169 (65.5)</td><td align="center" valign="top" rowspan="1" colspan="1">&lt;&#160;0.001</td><td align="center" valign="top" rowspan="1" colspan="1">1044 (35.5)</td><td align="center" valign="top" rowspan="1" colspan="1">2093 (35.7)</td><td align="center" valign="top" rowspan="1" colspan="1">0.925</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Prefrail</td><td align="center" valign="top" rowspan="1" colspan="1">47,284 (34.0%)</td><td align="center" valign="top" rowspan="1" colspan="1">1840 (62.5)</td><td align="center" valign="top" rowspan="1" colspan="1">45,444 (33.4)</td><td align="center" valign="top" rowspan="1" colspan="1">&lt;&#160;0.001</td><td align="center" valign="top" rowspan="1" colspan="1">1839 (62.5)</td><td align="center" valign="top" rowspan="1" colspan="1">3657 (62.4)</td><td align="center" valign="top" rowspan="1" colspan="1">0.925</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Frail</td><td align="center" valign="top" rowspan="1" colspan="1">1483 (1.1%)</td><td align="center" valign="top" rowspan="1" colspan="1">60 (2.0)</td><td align="center" valign="top" rowspan="1" colspan="1">1423 (1.0)</td><td align="center" valign="top" rowspan="1" colspan="1">&lt;&#160;0.001</td><td align="center" valign="top" rowspan="1" colspan="1">60 (2.0)</td><td align="center" valign="top" rowspan="1" colspan="1">113 (1.9)</td><td align="center" valign="top" rowspan="1" colspan="1">0.925</td></tr><tr><td colspan="8" align="left" valign="top" rowspan="1">Rurality</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Metro</td><td align="center" valign="top" rowspan="1" colspan="1">118,016&#160;(84.9%)</td><td align="center" valign="top" rowspan="1" colspan="1">2412 (81.9)</td><td align="center" valign="top" rowspan="1" colspan="1">115,604 (85.0)</td><td align="center" valign="top" rowspan="1" colspan="1">&lt;&#160;0.001</td><td align="center" valign="top" rowspan="1" colspan="1">2411 (81.9)</td><td align="center" valign="top" rowspan="1" colspan="1">4853 (82.8)</td><td align="center" valign="top" rowspan="1" colspan="1">0.322</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Nonmetro</td><td align="center" valign="top" rowspan="1" colspan="1">20,964 (15.1%)</td><td align="center" valign="top" rowspan="1" colspan="1">532 (18.1)</td><td align="center" valign="top" rowspan="1" colspan="1">20,432 (15.0)</td><td align="center" valign="top" rowspan="1" colspan="1">&lt;&#160;0.001</td><td align="center" valign="top" rowspan="1" colspan="1">532 (18.1)</td><td align="center" valign="top" rowspan="1" colspan="1">1010 (17.2)</td><td align="center" valign="top" rowspan="1" colspan="1">0.322</td></tr><tr><td colspan="8" align="left" valign="top" rowspan="1">Procedure</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">AAA</td><td align="center" valign="top" rowspan="1" colspan="1">4459 (3.3%)</td><td align="center" valign="top" rowspan="1" colspan="1">77 (2.6)</td><td align="center" valign="top" rowspan="1" colspan="1">4382 (3.2)</td><td align="center" valign="top" rowspan="1" colspan="1">&lt;&#160;0.001</td><td align="center" valign="top" rowspan="1" colspan="1">77 (2.6)</td><td align="center" valign="top" rowspan="1" colspan="1">141 (2.4)</td><td align="center" valign="top" rowspan="1" colspan="1">0.970</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">CABG</td><td align="center" valign="top" rowspan="1" colspan="1">39,516 (28.4%)</td><td align="center" valign="top" rowspan="1" colspan="1">1627 (55.3)</td><td align="center" valign="top" rowspan="1" colspan="1">37,889 (27.9)</td><td align="center" valign="top" rowspan="1" colspan="1">&lt;&#160;0.001</td><td align="center" valign="top" rowspan="1" colspan="1">1627 (55.3)</td><td align="center" valign="top" rowspan="1" colspan="1">3247 (55.4)</td><td align="center" valign="top" rowspan="1" colspan="1">0.970</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Colectomy</td><td align="center" valign="top" rowspan="1" colspan="1">74,251 (53.4%)</td><td align="center" valign="top" rowspan="1" colspan="1">935 (31.8)</td><td align="center" valign="top" rowspan="1" colspan="1">73,316 (53.9)</td><td align="center" valign="top" rowspan="1" colspan="1">&lt;&#160;0.001</td><td align="center" valign="top" rowspan="1" colspan="1">935 (31.8)</td><td align="center" valign="top" rowspan="1" colspan="1">1875 (32.0)</td><td align="center" valign="top" rowspan="1" colspan="1">0.970</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Pneumonectomy</td><td align="center" valign="top" rowspan="1" colspan="1">4881 (3.5%)</td><td align="center" valign="top" rowspan="1" colspan="1">101 (3.4)</td><td align="center" valign="top" rowspan="1" colspan="1">4780 (3.5)</td><td align="center" valign="top" rowspan="1" colspan="1">&lt;&#160;0.001</td><td align="center" valign="top" rowspan="1" colspan="1">101 (3.4)</td><td align="center" valign="top" rowspan="1" colspan="1">192 (3.3)</td><td align="center" valign="top" rowspan="1" colspan="1">0.970</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Pancreatectomy</td><td align="center" valign="top" rowspan="1" colspan="1">15,873 (11.4%)</td><td align="center" valign="top" rowspan="1" colspan="1">204 (6.9)</td><td align="center" valign="top" rowspan="1" colspan="1">15,669 (11.5)</td><td align="center" valign="top" rowspan="1" colspan="1">&lt;&#160;0.001</td><td align="center" valign="top" rowspan="1" colspan="1">203 (6.9)</td><td align="center" valign="top" rowspan="1" colspan="1">408 (7.0)</td><td align="center" valign="top" rowspan="1" colspan="1">0.970</td></tr></tbody></table><table-wrap-foot id="wjs12484-ntgp-0001"><fn id="wjs12484-note-0002"><p>Abbreviations: AAA, abdominal aortic aneurysm; CABG, coronary artery bypass graft; CCI, Charlson Comorbidity Index; GLP&#8208;1RA, glucagon&#8208;like peptide&#8208;1 receptor agonist; HMO, health maintenance organization; IQR, interquartile range; metro, metropolitan; POS, point of service plan; PPO, preferred provider organization; and SD, standard deviation.</p></fn><fn id="wjs12484-note-0003"><label>
<sup>a</sup>
</label><p>Including, COBRA, long&#8208;term disability, surviving spouse/depend, or other/unknown.</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="wjs12484-tbl-0002" content-type="TABLE" orientation="portrait"><label>TABLE 2</label><caption><p>Additional clinical characteristics of patients who underwent complex surgical procedures relative to glucagon&#8208;like peptide&#8208;1 receptor agonists initiation.</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><thead valign="bottom"><tr><th rowspan="2" style="border-bottom:solid 1px #000000" align="left" valign="bottom" colspan="1">Patient characteristics</th><th align="center" valign="bottom" rowspan="1" colspan="1"/><th style="border-bottom:solid 1px #000000" colspan="3" align="center" valign="bottom" rowspan="1">Unmatched</th><th style="border-bottom:solid 1px #000000" colspan="3" align="center" valign="bottom" rowspan="1">Matched</th></tr><tr style="border-bottom:solid 1px #000000"><th align="center" valign="bottom" rowspan="1" colspan="1">Total <italic toggle="yes">N</italic>&#160;=&#160;138,980</th><th align="center" valign="bottom" rowspan="1" colspan="1">GLP&#8208;1RA <italic toggle="yes">N</italic>&#160;=&#160;2944</th><th align="center" valign="bottom" rowspan="1" colspan="1">Non GLP&#8208;1RA <italic toggle="yes">N</italic>&#160;=&#160;136,036</th><th align="center" valign="bottom" rowspan="1" colspan="1">
<italic toggle="yes">p</italic>&#8208;value</th><th align="center" valign="bottom" rowspan="1" colspan="1">GLP&#8208;1RA <italic toggle="yes">N</italic>&#160;=&#160;2943</th><th align="center" valign="bottom" rowspan="1" colspan="1">Non GLP&#8208;1RA <italic toggle="yes">N</italic>&#160;=&#160;5863</th><th align="center" valign="bottom" rowspan="1" colspan="1">
<italic toggle="yes">p</italic>&#8208;value</th></tr></thead><tbody valign="top"><tr><td align="left" valign="top" rowspan="1" colspan="1">Myocardial infarction</td><td align="center" valign="top" rowspan="1" colspan="1">17,223&#160;(12.4%)</td><td align="center" valign="top" rowspan="1" colspan="1">584 (19.8)</td><td align="center" valign="top" rowspan="1" colspan="1">16,639 (12.2)</td><td align="center" valign="top" rowspan="1" colspan="1">&lt;&#160;0.001</td><td align="center" valign="top" rowspan="1" colspan="1">584 (19.8)</td><td align="center" valign="top" rowspan="1" colspan="1">1121 (19.1)</td><td align="center" valign="top" rowspan="1" colspan="1">0.418</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Congestive heart failure</td><td align="center" valign="top" rowspan="1" colspan="1">13,480 (9.7%)</td><td align="center" valign="top" rowspan="1" colspan="1">619 (21.0)</td><td align="center" valign="top" rowspan="1" colspan="1">12,861 (9.5)</td><td align="center" valign="top" rowspan="1" colspan="1">&lt;&#160;0.001</td><td align="center" valign="top" rowspan="1" colspan="1">619 (21.0)</td><td align="center" valign="top" rowspan="1" colspan="1">1232 (21.0)</td><td align="center" valign="top" rowspan="1" colspan="1">0.418</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Peripheral vascular disease</td><td align="center" valign="top" rowspan="1" colspan="1">4603 (3.3%)</td><td align="center" valign="top" rowspan="1" colspan="1">103 (3.5)</td><td align="center" valign="top" rowspan="1" colspan="1">4500 (3.3)</td><td align="center" valign="top" rowspan="1" colspan="1">0.567</td><td align="center" valign="top" rowspan="1" colspan="1">103 (3.5)</td><td align="center" valign="top" rowspan="1" colspan="1">226 (3.9)</td><td align="center" valign="top" rowspan="1" colspan="1">0.408</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Cerebrovascular disease</td><td align="center" valign="top" rowspan="1" colspan="1">8169 (5.9%)</td><td align="center" valign="top" rowspan="1" colspan="1">319 (10.8)</td><td align="center" valign="top" rowspan="1" colspan="1">7850 (5.8)</td><td align="center" valign="top" rowspan="1" colspan="1">&lt;&#160;0.001</td><td align="center" valign="top" rowspan="1" colspan="1">319 (10.8)</td><td align="center" valign="top" rowspan="1" colspan="1">640 (10.9)</td><td align="center" valign="top" rowspan="1" colspan="1">0.913</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Dementia</td><td align="center" valign="top" rowspan="1" colspan="1">90 (0.1%)</td><td align="center" valign="top" rowspan="1" colspan="1">3 (0.1)</td><td align="center" valign="top" rowspan="1" colspan="1">87 (0.1)</td><td align="center" valign="top" rowspan="1" colspan="1">0.423</td><td align="center" valign="top" rowspan="1" colspan="1">3 (0.1)</td><td align="center" valign="top" rowspan="1" colspan="1">3 (0.1)</td><td align="center" valign="top" rowspan="1" colspan="1">0.807</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Hemiplegia or paraplegia</td><td align="center" valign="top" rowspan="1" colspan="1">685 (0.5%)</td><td align="center" valign="top" rowspan="1" colspan="1">20 (0.7)</td><td align="center" valign="top" rowspan="1" colspan="1">665 (0.5)</td><td align="center" valign="top" rowspan="1" colspan="1">0.144</td><td align="center" valign="top" rowspan="1" colspan="1">20 (0.7)</td><td align="center" valign="top" rowspan="1" colspan="1">44 (0.8)</td><td align="center" valign="top" rowspan="1" colspan="1">0.712</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Diabetes mellitus type 1</td><td align="center" valign="top" rowspan="1" colspan="1">1087 (0.8%)</td><td align="center" valign="top" rowspan="1" colspan="1">43 (1.5)</td><td align="center" valign="top" rowspan="1" colspan="1">1044 (0.8)</td><td align="center" valign="top" rowspan="1" colspan="1">&lt;&#160;0.001</td><td align="center" valign="top" rowspan="1" colspan="1">43 (1.5)</td><td align="center" valign="top" rowspan="1" colspan="1">78 (1.3)</td><td align="center" valign="top" rowspan="1" colspan="1">0.619</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Diabetes mellitus type 2</td><td align="center" valign="top" rowspan="1" colspan="1">35,997 (25.9%)</td><td align="center" valign="top" rowspan="1" colspan="1">2844 (96.6)</td><td align="center" valign="top" rowspan="1" colspan="1">33,153 (24.4)</td><td align="center" valign="top" rowspan="1" colspan="1">&lt;&#160;0.001</td><td align="center" valign="top" rowspan="1" colspan="1">2843 (96.6)</td><td align="center" valign="top" rowspan="1" colspan="1">5663 (96.6)</td><td align="center" valign="top" rowspan="1" colspan="1">0.974</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Hypertension</td><td align="center" valign="top" rowspan="1" colspan="1">62,736 (45.1%)</td><td align="center" valign="top" rowspan="1" colspan="1">1910 (64.9)</td><td align="center" valign="top" rowspan="1" colspan="1">60,826 (44.7)</td><td align="center" valign="top" rowspan="1" colspan="1">&lt;&#160;0.001</td><td align="center" valign="top" rowspan="1" colspan="1">1909 (64.9)</td><td align="center" valign="top" rowspan="1" colspan="1">3841 (65.5)</td><td align="center" valign="top" rowspan="1" colspan="1">0.548</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Obesity</td><td align="center" valign="top" rowspan="1" colspan="1">8744 (6.3%)</td><td align="center" valign="top" rowspan="1" colspan="1">497 (16.9)</td><td align="center" valign="top" rowspan="1" colspan="1">8247 (6.1)</td><td align="center" valign="top" rowspan="1" colspan="1">&lt;&#160;0.001</td><td align="center" valign="top" rowspan="1" colspan="1">496 (16.9)</td><td align="center" valign="top" rowspan="1" colspan="1">975 (16.6)</td><td align="center" valign="top" rowspan="1" colspan="1">0.790</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Dyslipidemia</td><td align="center" valign="top" rowspan="1" colspan="1">45,278 (32.6%)</td><td align="center" valign="top" rowspan="1" colspan="1">1576 (53.5)</td><td align="center" valign="top" rowspan="1" colspan="1">43,702 (32.1)</td><td align="center" valign="top" rowspan="1" colspan="1">&lt;&#160;0.001</td><td align="center" valign="top" rowspan="1" colspan="1">1575 (53.5)</td><td align="center" valign="top" rowspan="1" colspan="1">3082 (52.6)</td><td align="center" valign="top" rowspan="1" colspan="1">0.400</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Chronic renal disease</td><td align="center" valign="top" rowspan="1" colspan="1">5394 (3.9%)</td><td align="center" valign="top" rowspan="1" colspan="1">198 (6.7)</td><td align="center" valign="top" rowspan="1" colspan="1">5196 (3.8)</td><td align="center" valign="top" rowspan="1" colspan="1">0.005</td><td align="center" valign="top" rowspan="1" colspan="1">198 (6.7)</td><td align="center" valign="top" rowspan="1" colspan="1">417 (7.1)</td><td align="center" valign="top" rowspan="1" colspan="1">0.504</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Chronic pulmonary disease</td><td align="center" valign="top" rowspan="1" colspan="1">19,955 (14.4%)</td><td align="center" valign="top" rowspan="1" colspan="1">348 (11.8)</td><td align="center" valign="top" rowspan="1" colspan="1">19,607 (14.4)</td><td align="center" valign="top" rowspan="1" colspan="1">&lt;&#160;0.001</td><td align="center" valign="top" rowspan="1" colspan="1">23 (0.8)</td><td align="center" valign="top" rowspan="1" colspan="1">50 (0.9)</td><td align="center" valign="top" rowspan="1" colspan="1">0.728</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Peptic ulcer disease</td><td align="center" valign="top" rowspan="1" colspan="1">927 (0.7%)</td><td align="center" valign="top" rowspan="1" colspan="1">18 (0.6)</td><td align="center" valign="top" rowspan="1" colspan="1">909 (0.7)</td><td align="center" valign="top" rowspan="1" colspan="1">0.708</td><td align="center" valign="top" rowspan="1" colspan="1">18 (0.6)</td><td align="center" valign="top" rowspan="1" colspan="1">29 (0.5)</td><td align="center" valign="top" rowspan="1" colspan="1">0.477</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Rheumatic disease</td><td align="center" valign="top" rowspan="1" colspan="1">1929 (1.4%)</td><td align="center" valign="top" rowspan="1" colspan="1">23 (0.8)</td><td align="center" valign="top" rowspan="1" colspan="1">1906 (1.4)</td><td align="center" valign="top" rowspan="1" colspan="1">0.005</td><td align="center" valign="top" rowspan="1" colspan="1">23 (0.8)</td><td align="center" valign="top" rowspan="1" colspan="1">50 (0.9)</td><td align="center" valign="top" rowspan="1" colspan="1">0.728</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">AIDS/HIV</td><td align="center" valign="top" rowspan="1" colspan="1">285 (0.2%)</td><td align="center" valign="top" rowspan="1" colspan="1">4 (0.1)</td><td align="center" valign="top" rowspan="1" colspan="1">281 (0.2)</td><td align="center" valign="top" rowspan="1" colspan="1">0.402</td><td align="center" valign="top" rowspan="1" colspan="1">4 (0.1)</td><td align="center" valign="top" rowspan="1" colspan="1">17 (0.3)</td><td align="center" valign="top" rowspan="1" colspan="1">0.162</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Any malignancy</td><td align="center" valign="top" rowspan="1" colspan="1">37,712 (27.1%)</td><td align="center" valign="top" rowspan="1" colspan="1">598 (20.3)</td><td align="center" valign="top" rowspan="1" colspan="1">37,114 (27.3)</td><td align="center" valign="top" rowspan="1" colspan="1">&lt;&#160;0.001</td><td align="center" valign="top" rowspan="1" colspan="1">597 (20.3)</td><td align="center" valign="top" rowspan="1" colspan="1">1199 (20.5)</td><td align="center" valign="top" rowspan="1" colspan="1">0.856</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Metastatic solid tumor</td><td align="center" valign="top" rowspan="1" colspan="1">13,515 (9.7%)</td><td align="center" valign="top" rowspan="1" colspan="1">193 (6.6)</td><td align="center" valign="top" rowspan="1" colspan="1">13,322 (9.8)</td><td align="center" valign="top" rowspan="1" colspan="1">&lt;&#160;0.001</td><td align="center" valign="top" rowspan="1" colspan="1">428 (7.3)</td><td align="center" valign="top" rowspan="1" colspan="1">193 (6.6)</td><td align="center" valign="top" rowspan="1" colspan="1">0.200</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Combination drugs</td><td align="center" valign="top" rowspan="1" colspan="1">1353 (1.0%)</td><td align="center" valign="top" rowspan="1" colspan="1">189 (6.4)</td><td align="center" valign="top" rowspan="1" colspan="1">1164 (0.9)</td><td align="center" valign="top" rowspan="1" colspan="1">&lt;&#160;0.001</td><td align="center" valign="top" rowspan="1" colspan="1">189 (6.4)</td><td align="center" valign="top" rowspan="1" colspan="1">364 (6.2)</td><td align="center" valign="top" rowspan="1" colspan="1">0.697</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Metformin</td><td align="center" valign="top" rowspan="1" colspan="1">1196 (0.9%)</td><td align="center" valign="top" rowspan="1" colspan="1">174 (5.9)</td><td align="center" valign="top" rowspan="1" colspan="1">1022 (0.8)</td><td align="center" valign="top" rowspan="1" colspan="1">&lt;&#160;0.001</td><td align="center" valign="top" rowspan="1" colspan="1">174 (5.9)</td><td align="center" valign="top" rowspan="1" colspan="1">353 (6.0)</td><td align="center" valign="top" rowspan="1" colspan="1">0.840</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">SGLT&#8208;2</td><td align="center" valign="top" rowspan="1" colspan="1">904 (0.7%)</td><td align="center" valign="top" rowspan="1" colspan="1">272 (9.2)</td><td align="center" valign="top" rowspan="1" colspan="1">632 (0.5)</td><td align="center" valign="top" rowspan="1" colspan="1">&lt;&#160;0.001</td><td align="center" valign="top" rowspan="1" colspan="1">271 (9.2)</td><td align="center" valign="top" rowspan="1" colspan="1">471 (8.0)</td><td align="center" valign="top" rowspan="1" colspan="1">0.061</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">DPP&#8208;4</td><td align="center" valign="top" rowspan="1" colspan="1">1984 (1.4%)</td><td align="center" valign="top" rowspan="1" colspan="1">200 (6.8)</td><td align="center" valign="top" rowspan="1" colspan="1">1784 (1.3)</td><td align="center" valign="top" rowspan="1" colspan="1">&lt;&#160;0.001</td><td align="center" valign="top" rowspan="1" colspan="1">200 (6.8)</td><td align="center" valign="top" rowspan="1" colspan="1">426 (7.3)</td><td align="center" valign="top" rowspan="1" colspan="1">0.418</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Sulphonylureas</td><td align="center" valign="top" rowspan="1" colspan="1">1090 (0.8%)</td><td align="center" valign="top" rowspan="1" colspan="1">115 (3.9)</td><td align="center" valign="top" rowspan="1" colspan="1">975 (0.7)</td><td align="center" valign="top" rowspan="1" colspan="1">&lt;&#160;0.001</td><td align="center" valign="top" rowspan="1" colspan="1">115 (3.9)</td><td align="center" valign="top" rowspan="1" colspan="1">212 (3.6)</td><td align="center" valign="top" rowspan="1" colspan="1">0.495</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Thiazolidinedione</td><td align="center" valign="top" rowspan="1" colspan="1">318 (0.2%)</td><td align="center" valign="top" rowspan="1" colspan="1">63 (2.1)</td><td align="center" valign="top" rowspan="1" colspan="1">255 (0.2)</td><td align="center" valign="top" rowspan="1" colspan="1">&lt;&#160;0.001</td><td align="center" valign="top" rowspan="1" colspan="1">63 (2.1)</td><td align="center" valign="top" rowspan="1" colspan="1">118 (2.0)</td><td align="center" valign="top" rowspan="1" colspan="1">0.690</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Statins</td><td align="center" valign="top" rowspan="1" colspan="1">3231 (2.3%)</td><td align="center" valign="top" rowspan="1" colspan="1">115 (3.9)</td><td align="center" valign="top" rowspan="1" colspan="1">3116 (2.3)</td><td align="center" valign="top" rowspan="1" colspan="1">&lt;&#160;0.001</td><td align="center" valign="top" rowspan="1" colspan="1">115 (3.9)</td><td align="center" valign="top" rowspan="1" colspan="1">228 (3.9)</td><td align="center" valign="top" rowspan="1" colspan="1">0.966</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Mild liver disease</td><td align="center" valign="top" rowspan="1" colspan="1">5957 (4.3%)</td><td align="center" valign="top" rowspan="1" colspan="1">151 (5.1)</td><td align="center" valign="top" rowspan="1" colspan="1">5806 (4.3)</td><td align="center" valign="top" rowspan="1" colspan="1">0.023</td><td align="center" valign="top" rowspan="1" colspan="1">151 (5.1)</td><td align="center" valign="top" rowspan="1" colspan="1">315 (5.4)</td><td align="center" valign="top" rowspan="1" colspan="1">0.633</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Severe liver disease</td><td align="center" valign="top" rowspan="1" colspan="1">503 (0.4%)</td><td align="center" valign="top" rowspan="1" colspan="1">12 (0.4)</td><td align="center" valign="top" rowspan="1" colspan="1">491 (0.4)</td><td align="center" valign="top" rowspan="1" colspan="1">0.677</td><td align="center" valign="top" rowspan="1" colspan="1">12 (0.4)</td><td align="center" valign="top" rowspan="1" colspan="1">21 (0.4)</td><td align="center" valign="top" rowspan="1" colspan="1">0.720</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">NAFLD</td><td align="center" valign="top" rowspan="1" colspan="1">3329 (2.4%)</td><td align="center" valign="top" rowspan="1" colspan="1">113 (3.8)</td><td align="center" valign="top" rowspan="1" colspan="1">3216 (2.4)</td><td align="center" valign="top" rowspan="1" colspan="1">&lt;&#160;0.001</td><td align="center" valign="top" rowspan="1" colspan="1">113 (3.8)</td><td align="center" valign="top" rowspan="1" colspan="1">226 (3.9)</td><td align="center" valign="top" rowspan="1" colspan="1">0.972</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">ALD</td><td align="center" valign="top" rowspan="1" colspan="1">2582 (1.9%)</td><td align="center" valign="top" rowspan="1" colspan="1">48 (1.6)</td><td align="center" valign="top" rowspan="1" colspan="1">2534 (1.9)</td><td align="center" valign="top" rowspan="1" colspan="1">0.356</td><td align="center" valign="top" rowspan="1" colspan="1">48 (1.6)</td><td align="center" valign="top" rowspan="1" colspan="1">103 (1.8)</td><td align="center" valign="top" rowspan="1" colspan="1">0.668</td></tr></tbody></table><table-wrap-foot id="wjs12484-ntgp-0002"><fn id="wjs12484-note-0004"><p>Abbreviations: AIDS, acquired immunodeficiency syndrome; ALD, alcohol&#8208;associated liver disease; DPP&#8208;4, dipeptidyl peptidase&#8208;4 inhibitors; GLP&#8208;1RA, glucagon&#8208;like peptide&#8208;1 receptor agonist; HIV, human immunodeficiency virus; NAFLD, nonalcoholic fatty liver disease; and SGLT&#8208;2, sodium&#8208;glucose cotransporter&#8208;2.</p></fn></table-wrap-foot></table-wrap><p>The primary outcome of interest was the development of complications within 30 days following surgery. The complications included sepsis, surgical site infections (SSIs), aspiration, hypoglycemia, pneumonia, ileus, venous thromboembolism (VTE), and acute respiratory, heart, or renal failure [<xref rid="wjs12484-bib-0007" ref-type="bibr">7</xref>, <xref rid="wjs12484-bib-0023" ref-type="bibr">23</xref>, <xref rid="wjs12484-bib-0024" ref-type="bibr">24</xref>, <xref rid="wjs12484-bib-0025" ref-type="bibr">25</xref>, <xref rid="wjs12484-bib-0026" ref-type="bibr">26</xref>, <xref rid="wjs12484-bib-0027" ref-type="bibr">27</xref>]. Readmission occurring within the 30&#160;days after the index surgery was a secondary outcome.</p></sec><sec id="wjs12484-sec-0040"><label>2.2</label><title>Statistical Analyses</title><p>Continuous variables were presented as median values with interquartile ranges (IQR) and were analyzed using either the Wilcoxon rank sum test or Student's t&#8208;test as appropriate. Similarly, categorical variables were summarized as frequencies and percentages and were compared using either the chi&#8208;squared test or Fisher's exact test [<xref rid="wjs12484-bib-0028" ref-type="bibr">28</xref>]. Propensity score matching (PSM) was employed to account for measured confounders and reduce selection bias when comparing outcomes of patients who did and did not receive GLP&#8208;1RA preceding surgery (Supplementary eMethods in Supporting Information&#160;<xref rid="wjs12484-sup-0001" ref-type="supplementary-material">S1</xref>). The patients were matched across baseline characteristics such as age, sex, region of residence, benefit plan type, employment status, CCI, claim&#8208;based frailty index, rurality, type of surgical procedure, and other clinical characteristics outlined in Table&#160;<xref rid="wjs12484-tbl-0002" ref-type="table">2</xref>. Following PSM, multivariable logistic regression models were employed to assess the association of GLP&#8208;1RA exposure with outcomes; odds ratio (OR) with 95% confidence intervals (CIs) were reported. All statistical analyses were conducted using SAS 9.4 (SAS Institute) with statistical significance set at a <italic toggle="yes">p</italic>&#8208;value of less than 0.05.</p></sec></sec><sec id="wjs12484-sec-0050"><label>3</label><title>Results</title><sec id="wjs12484-sec-0060"><label>3.1</label><title>Baseline Characteristics</title><p>A total of 138,980 patients underwent CABG (<italic toggle="yes">n</italic>&#160;=&#160;39,516, 28.4%), pneumonectomy (<italic toggle="yes">n</italic>&#160;=&#160;4,881, 3.5%), AAA repair (<italic toggle="yes">n</italic>&#160;=&#160;4,459, 3.3%), pancreatectomy (<italic toggle="yes">n</italic>&#160;=&#160;15,873, 11.4%), and colectomy (<italic toggle="yes">n</italic>&#160;=&#160;74,251, 53.4%). Median age was 58&#160;years (IQR: 53&#8211;61), most patients were male (<italic toggle="yes">n</italic>&#160;=&#160;80,871, 58.2%), had a CCI score of &#8804;&#160;2 (<italic toggle="yes">n</italic>&#160;=&#160;81,675, 58.8%), and were retirees (<italic toggle="yes">n</italic>&#160;=&#160;48,886, 35.2%). Most patients were enrolled in a preferred provider organization plan (<italic toggle="yes">n</italic>&#160;=&#160;79,839, 57.4%), followed by health maintenance organizations (<italic toggle="yes">n</italic>&#160;=&#160;15,318, 11.0%), point of service plans (<italic toggle="yes">n</italic>&#160;=&#160;9,788, 7.0%), and comprehensive plans (<italic toggle="yes">n</italic>&#160;=&#160;5,694, 4.1%); the remainder were enrolled in other benefit plans (<italic toggle="yes">n</italic>&#160;=&#160;28,341, 20.4%). Moreover, patients were primarily categorized as nonfrail (<italic toggle="yes">n</italic>&#160;=&#160;90,213, 64.9%) and prefrail (<italic toggle="yes">n</italic>&#160;=&#160;47,284, 34.0%), with only a few individuals categorized as frail (<italic toggle="yes">n</italic>&#160;=&#160;1,483, 1.1%). Among other baseline characteristics, 25.9% (<italic toggle="yes">n</italic>&#160;=&#160;35,997) of patients had a history of type 2 DM, 45.1% (<italic toggle="yes">n</italic>&#160;=&#160;62,736) had hypertension (HTN), 32.6% (<italic toggle="yes">n</italic>&#160;=&#160;45,278) had an abnormal lipid profile, 6.3% (<italic toggle="yes">n</italic>&#160;=&#160;8744) were obese, and 27.1% (37,712) of individuals had a malignancy. Furthermore, 12.4% (<italic toggle="yes">n</italic>&#160;=&#160;17,223) had a history of myocardial infarction, 9.7% (<italic toggle="yes">n</italic>&#160;=&#160;13,480) had congestive heart failure, 5.9% (<italic toggle="yes">n</italic>&#160;=&#160;8169) had cerebrovascular disease, and 2.4% (<italic toggle="yes">n</italic>&#160;=&#160;3329) had nonalcoholic fatty liver disease (NAFLD).</p><p>Overall, 2.2% (<italic toggle="yes">n</italic>&#160;=&#160;2944) of the patients were exposed to GLP&#8208;1RA prior to surgery. Compared with patients who had no GLP&#8208;1RA exposure, individuals exposed to GLP&#8208;1RA were more likely to be female (41.9% vs. 39.1%), older (58 vs. 56&#160;years), and retirees (35.3% vs. 27.8%) (all <italic toggle="yes">p</italic>&#160;&lt;&#160;0.05). Patients exposed to GLP&#8208;1RA had a higher baseline comorbidity burden (CCI: 56.6% vs. 40.9%) and a higher claim&#8208;based frailty (2.0 vs. 1.0) (both <italic toggle="yes">p</italic>&#160;&lt;&#160;0.001). The patterns of GLP&#8208;1RA exposure also varied depending on the type of surgery (CABG: 55.3% vs. 27.9%; pneumonectomy: 3.4% vs. 3.5%; AAA repair: 2.6% vs. 3.2%; pancreatectomy: 6.9% vs. 11.5%; colectomy: 31.8% vs. 53.9%; <italic toggle="yes">p</italic>&#160;&lt;&#160;0.001). Perhaps not surprisingly, individuals with type 2 DM (96.6% vs. 24.4%), HTN (64.9% vs. 44.7%), obesity (16.9% vs. 6.1%), dyslipidemia (53.5% vs. 32.1%), and NAFLD (3.8% vs. 2.4%) were more likely to take GLP&#8208;1RA (all <italic toggle="yes">p</italic>&#160;&lt;&#160;0.001). Similarly, patients with myocardial infarction (19.8% vs. 12.2%), congestive heart failure (21.0% vs. 9.5%), and cerebrovascular disease (10.8% vs. 5.8%) were also more likely to take GLP&#8208;1RA (<italic toggle="yes">p</italic>&#160;&lt;&#160;0.001). In contrast, patients with a baseline malignancy (20.3% vs. 27.3%; <italic toggle="yes">p</italic>&#160;&lt;&#160;0.001) were less likely to be on GLP&#8208;1RA before surgery. Additionally, patients who took GLP&#8208;1RA had higher concurrent use of other antiglycemic medications such as sodium&#8208;glucose cotransporter&#8208;2 inhibitors (9.2% vs. 0.5%), dipeptidyl peptidase&#8208;4 inhibitors (6.8% vs. 1.3%), sulphonylureas drugs (3.9% vs. 0.7%), and metformin (5.9% vs. 0.8%) (all <italic toggle="yes">p</italic>&#160;&lt;&#160;0.001).</p><p>Overall, 36.5% (<italic toggle="yes">n</italic>&#160;=&#160;50,724) of patients experienced some type of complication in the postoperative period. The most common complications included acute heart failure (<italic toggle="yes">n</italic>&#160;=&#160;14,494, 10.4%), ileus (<italic toggle="yes">n</italic>&#160;=&#160;13,478, 9.7%), respiratory failure (<italic toggle="yes">n</italic>&#160;=&#160;12,167, 8.8%), renal failure (<italic toggle="yes">n</italic>&#160;=&#160;9,017, 6.5%), SSI (<italic toggle="yes">n</italic>&#160;=&#160;7,431, 5.3%), sepsis (<italic toggle="yes">n</italic>&#160;=&#160;6,385, 4.6%), pneumonia (<italic toggle="yes">n</italic>&#160;=&#160;4,783, 3.4%), and VTE (<italic toggle="yes">n</italic>&#160;=&#160;3,609, 2.6%). Other less common complications were aspiration (<italic toggle="yes">n</italic>&#160;=&#160;625, 0.4%) and hypoglycemia (<italic toggle="yes">n</italic>&#160;=&#160;283, 0.2%). In addition, 9.8% (<italic toggle="yes">n</italic>&#160;=&#160;13,583) of patients were readmitted within 30&#160;days following surgery.</p><p>After adjusting for measured confounders using PSM, cases were effectively matched with controls, which mitigated variations in baseline clinicodemographic characteristics (all <italic toggle="yes">p</italic>&#160;&gt;&#160;0.05) (Table&#160;<xref rid="wjs12484-tbl-0001" ref-type="table">1</xref>). Subsequently, no differences were noted in the incidence of overall complications among GLP&#8208;1RA users and nonusers (GLP&#8208;1RA: 44.5% vs. no GLP&#8208;1RA: 44.8%; <italic toggle="yes">p</italic>&#160;=&#160;0.841) (Figure&#160;<xref rid="wjs12484-fig-0002" ref-type="fig">2</xref>). Specifically, the incidence of sepsis (3.9% vs. 4.6%), SSI (4.2% vs. 5.4%), and hypoglycemia (0.2% vs. 0.1%) as well as most other complications was similar among patients who did and did not receive GLP&#8208;1RA before surgery (all <italic toggle="yes">p</italic>&#160;&gt;&#160;0.05) (Table&#160;<xref rid="wjs12484-tbl-0003" ref-type="table">3</xref>). Although there was a slight difference in the incidence of ileus (GLP&#8208;1RA: 5.3% vs. no GLP&#8208;1RA: 6.7%; <italic toggle="yes">p</italic>&#160;=&#160;0.012) and aspiration (GLP&#8208;1RA: 0.3% vs. no GLP&#8208;1RA: 0.6%; <italic toggle="yes">p</italic>&#160;=&#160;0.039), the clinical significance of these small differences was likely minimal (Figure&#160;<xref rid="wjs12484-fig-0003" ref-type="fig">3</xref>). On multivariable analysis, GLP&#8208;1RA exposure was not associated with higher odds of complications (OR 0.99 95% CI 0.91&#8211;1.08; <italic toggle="yes">p</italic>&#160;=&#160;0.841) (Supplementary Table&#160;<xref rid="wjs12484-sup-0001" ref-type="supplementary-material">S1</xref>). There was also no difference in the likelihood of a 30&#8208;day readmission (GLP&#8208;1RA: 11.9% vs. no GLP&#8208;1RA: 11.8%; <italic toggle="yes">p</italic>&#160;=&#160;0.865). Additionally, stratified analyses were performed outlined in Supplementary Table&#160;<xref rid="wjs12484-sup-0001" ref-type="supplementary-material">S2</xref>.</p><fig position="float" fig-type="FIGURE" id="wjs12484-fig-0002" orientation="portrait"><label>FIGURE 2</label><caption><p>Adjusted risk of 30&#8208;day complications following surgery relative to glucagon&#8208;like peptide&#8208;1 receptor agonist (GLP&#8208;1RA) use.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-5" orientation="portrait" xlink:href="WJS-49-698-g003.jpg"/></fig><table-wrap position="float" id="wjs12484-tbl-0003" content-type="TABLE" orientation="portrait"><label>TABLE 3</label><caption><p>Outcomes of patients who underwent complex surgical procedures relative to glucagon&#8208;like peptide&#8208;1 receptor agonists initiation.</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><thead valign="bottom"><tr><th rowspan="2" style="border-bottom:solid 1px #000000" align="left" valign="bottom" colspan="1">Outcomes</th><th align="center" valign="bottom" rowspan="1" colspan="1"/><th style="border-bottom:solid 1px #000000" colspan="3" align="center" valign="bottom" rowspan="1">Unmatched</th><th style="border-bottom:solid 1px #000000" colspan="3" align="center" valign="bottom" rowspan="1">Matched</th></tr><tr style="border-bottom:solid 1px #000000"><th align="center" valign="bottom" rowspan="1" colspan="1">Total <italic toggle="yes">N</italic>&#160;=&#160;138,980</th><th align="center" valign="bottom" rowspan="1" colspan="1">GLP&#8208;1RA <italic toggle="yes">N</italic>&#160;=&#160;2944</th><th align="center" valign="bottom" rowspan="1" colspan="1">Non GLP&#8208;1RA <italic toggle="yes">N</italic>&#160;=&#160;136,036</th><th align="center" valign="bottom" rowspan="1" colspan="1">
<italic toggle="yes">p</italic>&#8208;value</th><th align="center" valign="bottom" rowspan="1" colspan="1">GLP&#8208;1RA</th><th align="center" valign="bottom" rowspan="1" colspan="1">Non GLP&#8208;1RA</th><th align="center" valign="bottom" rowspan="1" colspan="1">
<italic toggle="yes">p</italic>&#8208;value</th></tr></thead><tbody valign="top"><tr><td align="left" valign="top" rowspan="1" colspan="1">Complications</td><td align="center" valign="top" rowspan="1" colspan="1">50,724 (36.5)</td><td align="center" valign="top" rowspan="1" colspan="1">1311 (44.5)</td><td align="center" valign="top" rowspan="1" colspan="1">49,413 (36.3)</td><td align="center" valign="top" rowspan="1" colspan="1">&lt;&#160;0.001</td><td align="center" valign="top" rowspan="1" colspan="1">1311 (44.6)</td><td align="center" valign="top" rowspan="1" colspan="1">2625 (11.8)</td><td align="center" valign="top" rowspan="1" colspan="1">0.865</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Sepsis</td><td align="center" valign="top" rowspan="1" colspan="1">6385 (4.6)</td><td align="center" valign="top" rowspan="1" colspan="1">114 (3.9)</td><td align="center" valign="top" rowspan="1" colspan="1">6281 (4.6)</td><td align="center" valign="top" rowspan="1" colspan="1">0.056</td><td align="center" valign="top" rowspan="1" colspan="1">114 (3.9)</td><td align="center" valign="top" rowspan="1" colspan="1">268 (4.6)</td><td align="center" valign="top" rowspan="1" colspan="1">0.130</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">SSI</td><td align="center" valign="top" rowspan="1" colspan="1">7431 (5.3)</td><td align="center" valign="top" rowspan="1" colspan="1">124 (4.2)</td><td align="center" valign="top" rowspan="1" colspan="1">7307 (5.4)</td><td align="center" valign="top" rowspan="1" colspan="1">0.006</td><td align="center" valign="top" rowspan="1" colspan="1">124 (4.2)</td><td align="center" valign="top" rowspan="1" colspan="1">259 (4.4)</td><td align="center" valign="top" rowspan="1" colspan="1">0.658</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Aspiration</td><td align="center" valign="top" rowspan="1" colspan="1">625 (0.4)</td><td align="center" valign="top" rowspan="1" colspan="1">8 (0.3)</td><td align="center" valign="top" rowspan="1" colspan="1">617 (0.5)</td><td align="center" valign="top" rowspan="1" colspan="1">0.145</td><td align="center" valign="top" rowspan="1" colspan="1">8 (0.3)</td><td align="center" valign="top" rowspan="1" colspan="1">35 (0.6)</td><td align="center" valign="top" rowspan="1" colspan="1">0.039</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Hypoglycemia</td><td align="center" valign="top" rowspan="1" colspan="1">283 (0.2)</td><td align="center" valign="top" rowspan="1" colspan="1">5 (0.2)</td><td align="center" valign="top" rowspan="1" colspan="1">278 (0.2)</td><td align="center" valign="top" rowspan="1" colspan="1">0.681</td><td align="center" valign="top" rowspan="1" colspan="1">5 (0.2)</td><td align="center" valign="top" rowspan="1" colspan="1">8 (0.1)</td><td align="center" valign="top" rowspan="1" colspan="1">0.700</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Ileus</td><td align="center" valign="top" rowspan="1" colspan="1">13,478 (9.7)</td><td align="center" valign="top" rowspan="1" colspan="1">157 (5.3)</td><td align="center" valign="top" rowspan="1" colspan="1">13,321 (9.8)</td><td align="center" valign="top" rowspan="1" colspan="1">&lt;&#160;0.001</td><td align="center" valign="top" rowspan="1" colspan="1">157 (5.3)</td><td align="center" valign="top" rowspan="1" colspan="1">393 (6.7)</td><td align="center" valign="top" rowspan="1" colspan="1">0.012</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Respiratory failure</td><td align="center" valign="top" rowspan="1" colspan="1">12,167 (8.8)</td><td align="center" valign="top" rowspan="1" colspan="1">410 (13.9)</td><td align="center" valign="top" rowspan="1" colspan="1">11,757 (8.6)</td><td align="center" valign="top" rowspan="1" colspan="1">&lt;&#160;0.001</td><td align="center" valign="top" rowspan="1" colspan="1">410 (13.9)</td><td align="center" valign="top" rowspan="1" colspan="1">795 (13.6)</td><td align="center" valign="top" rowspan="1" colspan="1">0.632</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Pneumonia</td><td align="center" valign="top" rowspan="1" colspan="1">4783 (3.4)</td><td align="center" valign="top" rowspan="1" colspan="1">138 (4.7)</td><td align="center" valign="top" rowspan="1" colspan="1">4645 (3.4)</td><td align="center" valign="top" rowspan="1" colspan="1">&lt;&#160;0.001</td><td align="center" valign="top" rowspan="1" colspan="1">138 (4.7)</td><td align="center" valign="top" rowspan="1" colspan="1">301 (5.1)</td><td align="center" valign="top" rowspan="1" colspan="1">0.366</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Acute heart failure</td><td align="center" valign="top" rowspan="1" colspan="1">14,494 (10.4)</td><td align="center" valign="top" rowspan="1" colspan="1">506 (17.2)</td><td align="center" valign="top" rowspan="1" colspan="1">13,988 (10.3)</td><td align="center" valign="top" rowspan="1" colspan="1">&lt;&#160;0.001</td><td align="center" valign="top" rowspan="1" colspan="1">506 (17.2)</td><td align="center" valign="top" rowspan="1" colspan="1">998 (17.0)</td><td align="center" valign="top" rowspan="1" colspan="1">0.840</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Acute renal failure</td><td align="center" valign="top" rowspan="1" colspan="1">9017 (6.5)</td><td align="center" valign="top" rowspan="1" colspan="1">354 (12.0)</td><td align="center" valign="top" rowspan="1" colspan="1">8663 (6.4)</td><td align="center" valign="top" rowspan="1" colspan="1">&lt;&#160;0.001</td><td align="center" valign="top" rowspan="1" colspan="1">354 (12.0)</td><td align="center" valign="top" rowspan="1" colspan="1">637 (10.9)</td><td align="center" valign="top" rowspan="1" colspan="1">0.103</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Venous thromboembolism</td><td align="center" valign="top" rowspan="1" colspan="1">3609 (2.6)</td><td align="center" valign="top" rowspan="1" colspan="1">91 (3.1)</td><td align="center" valign="top" rowspan="1" colspan="1">3518 (2.6)</td><td align="center" valign="top" rowspan="1" colspan="1">0.088</td><td align="center" valign="top" rowspan="1" colspan="1">91 (3.1)</td><td align="center" valign="top" rowspan="1" colspan="1">160 (2.7)</td><td align="center" valign="top" rowspan="1" colspan="1">0.933</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Readmission</td><td align="center" valign="top" rowspan="1" colspan="1">13,583 (9.8)</td><td align="center" valign="top" rowspan="1" colspan="1">350 (11.9)</td><td align="center" valign="top" rowspan="1" colspan="1">13,233 (9.7)</td><td align="center" valign="top" rowspan="1" colspan="1">&lt;&#160;0.001</td><td align="center" valign="top" rowspan="1" colspan="1">350 (11.9)</td><td align="center" valign="top" rowspan="1" colspan="1">690 (11.8)</td><td align="center" valign="top" rowspan="1" colspan="1">0.865</td></tr></tbody></table><table-wrap-foot id="wjs12484-ntgp-0003"><fn id="wjs12484-note-0005"><p>Abbreviations: GLP&#8208;1RA, glucagon&#8208;like peptide&#8208;1 receptor agonist; Postop, postoperative; and SSI, surgical site infection.</p></fn></table-wrap-foot></table-wrap><fig position="float" fig-type="FIGURE" id="wjs12484-fig-0003" orientation="portrait"><label>FIGURE 3</label><caption><p>Boxplot depicting the adjusted probability of ileus and aspiration following complex surgical procedure relative to glucagon&#8208;like peptide&#8208;1 receptor agonist (GLP&#8208;1RA) use.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-7" orientation="portrait" xlink:href="WJS-49-698-g001.jpg"/></fig></sec></sec><sec id="wjs12484-sec-0070"><label>4</label><title>Discussion</title><p>Over the past decade, there has been an increased focus on improving the quality of surgical care and reducing postoperative complications [<xref rid="wjs12484-bib-0029" ref-type="bibr">29</xref>, <xref rid="wjs12484-bib-0030" ref-type="bibr">30</xref>]. Consequently, there is a growing emphasis on understanding the preoperative and perioperative risk factors that may contribute to surgical morbidity [<xref rid="wjs12484-bib-0031" ref-type="bibr">31</xref>]. Despite these efforts, complications particularly after major surgery continue to be a concern for both patients and clinicians [<xref rid="wjs12484-bib-0015" ref-type="bibr">15</xref>, <xref rid="wjs12484-bib-0031" ref-type="bibr">31</xref>, <xref rid="wjs12484-bib-0032" ref-type="bibr">32</xref>]. In fact, roughly one in every four patient undergoing major surgery experiences a surgical complication [<xref rid="wjs12484-bib-0033" ref-type="bibr">33</xref>]. Notably, medications used for comorbid conditions, such as DM, can differentially impact surgical outcomes [<xref rid="wjs12484-bib-0007" ref-type="bibr">7</xref>, <xref rid="wjs12484-bib-0034" ref-type="bibr">34</xref>]. This is particularly true for newer drug classes that may be effective for one disorder but have complex interactions during transient nonhomeostatic states such as surgical episodes [<xref rid="wjs12484-bib-0035" ref-type="bibr">35</xref>]. One such example is GLP&#8208;1RA medications, which have recently gained popularity as a treatment of choice for multiple metabolic disorders [<xref rid="wjs12484-bib-0001" ref-type="bibr">1</xref>, <xref rid="wjs12484-bib-0002" ref-type="bibr">2</xref>, <xref rid="wjs12484-bib-0009" ref-type="bibr">9</xref>]. Nonetheless, the association of GLP&#8208;1RA with the incidence of postoperative complications remains a topic of debate [<xref rid="wjs12484-bib-0003" ref-type="bibr">3</xref>, <xref rid="wjs12484-bib-0006" ref-type="bibr">6</xref>]. As such, the current study was important as it characterized the association of GLP&#8208;1RA initiation status with outcomes following major surgical procedures. Notably, outcomes were comparable among the patients who did and did not receive GLP&#8208;1RA before the surgical procedure. In fact, on stratified analysis, patients who received care compliant with American Society of Anesthesiologists guidelines and stopped GLP&#8208;1RA before surgery had outcomes similar to individuals who continued using GLP&#8208;1RA up until the time of surgery.</p><p>Previous studies have reported that GLP&#8208;1RA drugs can slow down the gastrointestinal system either by directly binding to receptors or indirectly through modulation of insulin&#8208;glucagon pathways [<xref rid="wjs12484-bib-0036" ref-type="bibr">36</xref>, <xref rid="wjs12484-bib-0037" ref-type="bibr">37</xref>]. In fact, this is the primary mechanism behind increased satiety, which can decrease food consumption and consequently assist in both glycemic control improvement as well as weight reduction [<xref rid="wjs12484-bib-0037" ref-type="bibr">37</xref>]. Nonetheless, there are concerns that this same mechanism of action can contribute to gastric content retention and increase complications related to anesthesia such as aspirations [<xref rid="wjs12484-bib-0038" ref-type="bibr">38</xref>]. To this end, Yeo et&#160;al. reported that patients with GLP&#8208;1RA usage had a 20% higher incidence of aspirations after endoscopic procedures [<xref rid="wjs12484-bib-0039" ref-type="bibr">39</xref>]. In contrast, Dixit et&#160;al. demonstrated that among patients undergoing common emergency surgical procedures, 7.5% experienced short&#8208;term respiratory complications, with no difference relative to GLP&#8208;1RA utilization [<xref rid="wjs12484-bib-0039" ref-type="bibr">39</xref>]. The current study noted that 10.9% of the patients experienced respiratory complications such as aspiration, pneumonia, or respiratory failure. Of note, there was no difference in the incidence of aspiration and pneumonia between the two groups, yet respiratory failure was slightly more common among patients taking GLP&#8208;1RA. Nonetheless, after adjusting for measured confounders, this difference was almost completely mitigated. Similarly, the difference in the incidence of ileus following surgery relative to GLP&#8208;1RA use was also clinically unremarkable. Odds of thromboembolism among patients with GLP&#8208;1RA versus without GLP&#8208;1RA exposure was also comparable (OR: 1.25 and 95% CI 0.87&#8211;1.79). In previous studies that used mice models, glucagon&#8208;like peptide&#8208;1 receptors had been demonstrated to cause inhibition of platelet aggregation in a nitric oxide&#8208;dependent manner [<xref rid="wjs12484-bib-0040" ref-type="bibr">40</xref>, <xref rid="wjs12484-bib-0041" ref-type="bibr">41</xref>]. Hence, some investigators had hypothesized that GLP&#8208;1RA drugs may reduce thromboembolic events [<xref rid="wjs12484-bib-0040" ref-type="bibr">40</xref>, <xref rid="wjs12484-bib-0041" ref-type="bibr">41</xref>].</p><p>Management of surgical patients can often be challenging, requiring optimization of metabolic profiles, particularly serum glucose levels [<xref rid="wjs12484-bib-0042" ref-type="bibr">42</xref>, <xref rid="wjs12484-bib-0043" ref-type="bibr">43</xref>]. Blood sugar management is important among patients with or without DM because high glucose levels have been independently associated with higher mortality and morbidity [<xref rid="wjs12484-bib-0042" ref-type="bibr">42</xref>, <xref rid="wjs12484-bib-0043" ref-type="bibr">43</xref>]. Among the morbidities attributed to poor glycemic control, sepsis and SSI are the most prominent [<xref rid="wjs12484-bib-0042" ref-type="bibr">42</xref>, <xref rid="wjs12484-bib-0044" ref-type="bibr">44</xref>, <xref rid="wjs12484-bib-0045" ref-type="bibr">45</xref>]. To this point, one preclinical trial reported Semaglutide to be more effective in reducing bone or joint infections versus other therapies [<xref rid="wjs12484-bib-0046" ref-type="bibr">46</xref>]. In another observational study, this association of GLP&#8208;1RA use with infection risk was only noted among patients undergoing total hip replacement, while there was no benefit of GLP&#8208;1RA in reducing SSI for total knee replacement [<xref rid="wjs12484-bib-0006" ref-type="bibr">6</xref>]. In the current study, 30&#8208;day risk of sepsis and SSI following a major surgical procedure was not associated with GLP&#8208;1RA exposure. The lack of difference may be partly explained by the focus on major procedures in this study, for which more aggressive measures, such as close supervision and higher use of prophylactic antibiotics, are employed to prevent potentially severe infections [<xref rid="wjs12484-bib-0047" ref-type="bibr">47</xref>].</p><p>According to ASA guidelines, it is recommended to discontinue GLP&#8208;1RA before elective surgery [<xref rid="wjs12484-bib-0014" ref-type="bibr">14</xref>]. For emergency procedures, in which timely discontinuation may not be possible, follow&#8208;up with an abdominal ultrasound to check for gastric residual contents is advised [<xref rid="wjs12484-bib-0014" ref-type="bibr">14</xref>]. In the current study, despite the vast majority of procedures being elective, one in every five patients continued taking GLP&#8208;1RA until surgery. In addition, use of perioperative abdominal ultrasound was similar among both groups (Supplementary Table&#160;<xref rid="wjs12484-sup-0001" ref-type="supplementary-material">S2</xref>). These results highlight the variability in practices across different hospitals [<xref rid="wjs12484-bib-0048" ref-type="bibr">48</xref>]. When weighing the achievement of optimal glycemic control along with potential multisystem benefits versus the risks of surgical complications that can or cannot occur, discontinuing the medication may not always be the preferred choice [<xref rid="wjs12484-bib-0012" ref-type="bibr">12</xref>, <xref rid="wjs12484-bib-0049" ref-type="bibr">49</xref>]. To this end, some policymakers and healthcare associations have advocated liberalizing current guidelines to withhold GLP&#8208;1RA prior to surgery [<xref rid="wjs12484-bib-0007" ref-type="bibr">7</xref>].</p><p>The findings of the current studies should be interpreted in light of several limitations. Retrospective administrative datasets rely on ICD and national drug codes, which can be prone to inaccurate data input and missing values [<xref rid="wjs12484-bib-0050" ref-type="bibr">50</xref>]. Therefore, there was a potential risk for misclassification bias and residual confounding. Additionally, the IBM MarketScan database is comprised of information on individuals and their dependents with employer&#8208;sponsored benefit plans. In turn, the data may have limited generalizability to patients who are either uninsured or are enrolled in government&#8208;sponsored health plans such as Medicare or Medicaid [<xref rid="wjs12484-bib-0019" ref-type="bibr">19</xref>]. Additionally, as an observational study, the findings should be classified as associations rather than causations. However, the use of a robust statistical method of PSM did mitigate confounding by indication [<xref rid="wjs12484-bib-0051" ref-type="bibr">51</xref>]. Data on granular patient&#8208;level factors (e.g., race/ethnicity) or clinical characteristics (e.g., severity of comorbidities) that may influence the effects of GLP&#8208;1RA could also not be assessed [<xref rid="wjs12484-bib-0052" ref-type="bibr">52</xref>]. Despite these limitations, the study offers valuable insights into the association between GLP&#8208;1RA and surgical outcomes, which would otherwise be difficult to investigate in clinical trials.</p><p>In conclusion, GLP&#8208;1RA use was not associated with an increased risk of complications following major surgical procedures even among patients who continued the medication up until the time of surgery. There may be a need to reconsider the guidelines and liberalize the use of GLP&#8208;1RA medications during the perioperative period.</p></sec><sec id="wjs12484-sec-0080"><title>Author Contributions</title><p>
<bold>Zayed Rashid:</bold> conceptualization, formal analysis, investigation, methodology, validation, visualization, writing&#8211;original draft, writing&#8211;review and editing. <bold>Selamawit Woldesenbet:</bold> conceptualization, data curation, formal analysis, investigation, methodology, software, validation, visualization, writing&#8211;original draft, writing&#8211;review and editing. <bold>Mujtaba Khalil:</bold> conceptualization, data curation, formal analysis, investigation, methodology, validation, writing&#8211;original draft, writing&#8211;review and editing. <bold>Abdullah Altaf:</bold> conceptualization, data curation, formal analysis, methodology, visualization, writing&#8211;original draft, writing&#8211;review and editing. <bold>Jun Kawashima:</bold> conceptualization, investigation, methodology, writing&#8211;original draft, writing&#8211;review and editing. <bold>Khalid Mumtaz:</bold> conceptualization, project administration, supervision, writing&#8211;original draft, writing&#8211;review &amp; editing. <bold>Timothy M. Pawlik:</bold> conceptualization, investigation, methodology, project administration, resources, supervision, validation, visualization, writing&#8211;original draft, writing&#8211;review and editing.</p></sec><sec id="wjs12484-sec-0100"><title>Ethics Statement</title><p>The need for informed consent for deidentified data was waived by the institutional review board of the Ohio State University.</p></sec><sec sec-type="COI-statement" id="wjs12484-sec-0110"><title>Conflicts of Interest</title><p>The authors declare no conflicts of interest.</p></sec><sec sec-type="supplementary-material"><title>Supporting information</title><supplementary-material id="wjs12484-sup-0001" position="float" content-type="local-data" orientation="portrait"><caption><p>Supporting Information S1</p></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="WJS-49-698-s001.docx" position="float" orientation="portrait"/></supplementary-material></sec></body><back><ack id="wjs12484-sec-0090"><title>Acknowledgments</title><p>The authors have nothing to report.</p></ack><sec sec-type="data-availability" id="wjs12484-sec-0130"><title>Data Availability Statement</title><p>The data for this study were obtained from the IBM MarketScan database. There are restrictions to the availability of this data, which are used under license for this study. Data can be accessed with the permission from the IBM MarketScan Commercial Database.</p></sec><ref-list content-type="cited-references" id="wjs12484-bibl-0001"><title>References</title><ref id="wjs12484-bib-0001"><label>1</label><mixed-citation publication-type="journal" id="wjs12484-cit-0001"><string-name name-style="western"><given-names>M. I.</given-names><surname>Elsaid</surname></string-name>, <string-name name-style="western"><given-names>Na</given-names><surname>Li</surname></string-name>, <string-name name-style="western"><given-names>S. A.</given-names><surname>Firkins</surname></string-name>, et&#160;al. &#8220;<article-title>Impacts of Glucagon&#8208;Like Peptide&#8208;1 Receptor Agonists on the Risk of Adverse Liver Outcomes in Patients With Metabolic Dysfunction&#8208;Associated Steatotic Liver Disease Cirrhosis and Type 2 Diabetes</article-title>,&#8221; <source>Alimentary Pharmacology &amp; Therapeutics</source><volume>59</volume>, no. <issue>9</issue> (<year>2024</year>): <fpage>1096</fpage>&#8211;<lpage>1110</lpage>, <pub-id pub-id-type="doi">10.1111/apt.17925</pub-id>.<pub-id pub-id-type="pmid">38538967</pub-id></mixed-citation></ref><ref id="wjs12484-bib-0002"><label>2</label><mixed-citation publication-type="journal" id="wjs12484-cit-0002"><string-name name-style="western"><given-names>C.</given-names><surname>Patel Chavez</surname></string-name>, <string-name name-style="western"><given-names>K.</given-names><surname>Cusi</surname></string-name>, and <string-name name-style="western"><given-names>S.</given-names><surname>Kadiyala</surname></string-name>, &#8220;<article-title>The Emerging Role of Glucagon&#8208;Like Peptide&#8208;1 Receptor Agonists for the Management of NAFLD</article-title>,&#8221; <source>Journal of Clinical Endocrinology &amp; Metabolism</source><volume>107</volume>, no. <issue>1</issue> (<year>2022</year>): <fpage>29</fpage>&#8211;<lpage>38</lpage>, <pub-id pub-id-type="doi">10.1210/clinem/dgab578</pub-id>.<pub-id pub-id-type="pmid">34406410</pub-id><pub-id pub-id-type="pmcid">PMC8684453</pub-id></mixed-citation></ref><ref id="wjs12484-bib-0003"><label>3</label><mixed-citation publication-type="journal" id="wjs12484-cit-0003"><string-name name-style="western"><given-names>D. C.</given-names><surname>Klonoff</surname></string-name>, <string-name name-style="western"><given-names>S. H.</given-names><surname>Kim</surname></string-name>, <string-name name-style="western"><given-names>R. J.</given-names><surname>Galindo</surname></string-name>, et&#160;al. &#8220;<article-title>Risks of Peri&#8208; and Postoperative Complications With Glucagon&#8208;Like Peptide&#8208;1 Receptor Agonists</article-title>,&#8221; <source>Diabetes, Obesity and Metabolism</source><volume>26</volume>, no. <issue>8</issue> (<year>2024</year>): <fpage>3128</fpage>&#8211;<lpage>3136</lpage>, <pub-id pub-id-type="doi">10.1111/dom.15636</pub-id>.<pub-id pub-id-type="pmcid">PMC12051400</pub-id><pub-id pub-id-type="pmid">38742898</pub-id></mixed-citation></ref><ref id="wjs12484-bib-0004"><label>4</label><mixed-citation publication-type="journal" id="wjs12484-cit-0004"><string-name name-style="western"><given-names>M. G.</given-names><surname>Nanna</surname></string-name>, <string-name name-style="western"><given-names>A. A.</given-names><surname>Kolkailah</surname></string-name>, <string-name name-style="western"><given-names>C.</given-names><surname>Page</surname></string-name>, <string-name name-style="western"><given-names>E. D.</given-names><surname>Peterson</surname></string-name>, and <string-name name-style="western"><given-names>A. M.</given-names><surname>Navar</surname></string-name>, &#8220;<article-title>Use of Sodium&#8208;Glucose Cotransporter 2 Inhibitors and Glucagonlike Peptide&#8208;1 Receptor Agonists in Patients With Diabetes and Cardiovascular Disease in Community Practice</article-title>,&#8221; <source>JAMA Cardiology</source><volume>8</volume>, no. <issue>1</issue> (<year>2023</year>): <fpage>89</fpage>&#8211;<lpage>95</lpage>, <pub-id pub-id-type="doi">10.1001/jamacardio.2022.3839</pub-id>.<pub-id pub-id-type="pmid">36322056</pub-id><pub-id pub-id-type="pmcid">PMC9631221</pub-id></mixed-citation></ref><ref id="wjs12484-bib-0005"><label>5</label><mixed-citation publication-type="journal" id="wjs12484-cit-0005"><string-name name-style="western"><given-names>J. J.</given-names><surname>Gorgojo&#8208;Mart&#237;nez</surname></string-name>, <string-name name-style="western"><given-names>P.</given-names><surname>Mezquita&#8208;Raya</surname></string-name>, <string-name name-style="western"><given-names>J.</given-names><surname>Carretero&#8208;G&#243;mez</surname></string-name>, et&#160;al. &#8220;<article-title>Clinical Recommendations to Manage Gastrointestinal Adverse Events in Patients Treated With Glp&#8208;1 Receptor Agonists: A Multidisciplinary Expert Consensus</article-title>,&#8221; <source>Journal of Clinical Medicine</source><volume>12</volume>, no. <issue>1</issue> (<year>2022</year>): <elocation-id>145</elocation-id>, <pub-id pub-id-type="doi">10.3390/jcm12010145</pub-id>.<pub-id pub-id-type="pmid">36614945</pub-id><pub-id pub-id-type="pmcid">PMC9821052</pub-id></mixed-citation></ref><ref id="wjs12484-bib-0006"><label>6</label><mixed-citation publication-type="journal" id="wjs12484-cit-0006"><string-name name-style="western"><given-names>A.</given-names><surname>Buddhiraju</surname></string-name>, <string-name name-style="western"><given-names>W.</given-names><surname>Kagabo</surname></string-name>, <string-name name-style="western"><given-names>H. S.</given-names><surname>Khanuja</surname></string-name>, <string-name name-style="western"><given-names>J. K.</given-names><surname>Oni</surname></string-name>, <string-name name-style="western"><given-names>L. E.</given-names><surname>Nikkel</surname></string-name>, and <string-name name-style="western"><given-names>V.</given-names><surname>Hegde</surname></string-name>, &#8220;<article-title>Decreased Risk of Readmission and Complications With Preoperative GLP&#8208;1 Analog Use in Patients Undergoing Primary Total Joint Arthroplasty</article-title>,&#8221; <source>Journal of Arthroplasty</source><volume>39</volume>, no. <issue>12</issue> (<year>2024</year>): <elocation-id>S0883540324005515</elocation-id>: Published online, <pub-id pub-id-type="doi">10.1016/j.arth.2024.05.079</pub-id>.<pub-id pub-id-type="pmid">38823516</pub-id></mixed-citation></ref><ref id="wjs12484-bib-0007"><label>7</label><mixed-citation publication-type="journal" id="wjs12484-cit-0007"><string-name name-style="western"><given-names>A. A.</given-names><surname>Dixit</surname></string-name>, <string-name name-style="western"><given-names>B. T.</given-names><surname>Bateman</surname></string-name>, <string-name name-style="western"><given-names>M. T.</given-names><surname>Hawn</surname></string-name>, <string-name name-style="western"><given-names>M. C.</given-names><surname>Odden</surname></string-name>, and <string-name name-style="western"><given-names>E. C.</given-names><surname>Sun</surname></string-name>, &#8220;<article-title>Preoperative GLP&#8208;1 Receptor Agonist Use and Risk of Postoperative Respiratory Complications</article-title>,&#8221; <source>JAMA</source><volume>331</volume>, no. <issue>19</issue> (<year>2024</year>): <fpage>1672</fpage>&#8211;<lpage>1673</lpage>, <pub-id pub-id-type="doi">10.1001/jama.2024.5003</pub-id>.<pub-id pub-id-type="pmid">38648036</pub-id><pub-id pub-id-type="pmcid">PMC11036309</pub-id></mixed-citation></ref><ref id="wjs12484-bib-0008"><label>8</label><mixed-citation publication-type="journal" id="wjs12484-cit-0008"><string-name name-style="western"><given-names>A. M.</given-names><surname>Lincoff</surname></string-name>, <string-name name-style="western"><given-names>K.</given-names><surname>Brown&#8208;Frandsen</surname></string-name>, <string-name name-style="western"><given-names>H. M.</given-names><surname>Colhoun</surname></string-name>, et&#160;al. &#8220;<article-title>Semaglutide and Cardiovascular Outcomes in Obesity Without Diabetes</article-title>,&#8221; <source>New England Journal of Medicine</source><volume>389</volume>, no. <issue>24</issue> (<year>2023</year>): <fpage>2221</fpage>&#8211;<lpage>2232</lpage>, <pub-id pub-id-type="doi">10.1056/NEJMoa2307563</pub-id>.<pub-id pub-id-type="pmid">37952131</pub-id></mixed-citation></ref><ref id="wjs12484-bib-0009"><label>9</label><mixed-citation publication-type="journal" id="wjs12484-cit-0009"><string-name name-style="western"><given-names>M. A.</given-names><surname>Nauck</surname></string-name>, <string-name name-style="western"><given-names>J. J.</given-names><surname>Meier</surname></string-name>, <string-name name-style="western"><given-names>M. A.</given-names><surname>Cavender</surname></string-name>, <string-name name-style="western"><given-names>M.</given-names><surname>Abd El Aziz</surname></string-name>, and <string-name name-style="western"><given-names>D. J.</given-names><surname>Drucker</surname></string-name>, &#8220;<article-title>Cardiovascular Actions and Clinical Outcomes With Glucagon&#8208;Like Peptide&#8208;1 Receptor Agonists and Dipeptidyl Peptidase&#8208;4 Inhibitors</article-title>,&#8221; <source>Circulation</source><volume>136</volume>, no. <issue>9</issue> (<year>2017</year>): <fpage>849</fpage>&#8211;<lpage>870</lpage>, <pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.117.028136</pub-id>.<pub-id pub-id-type="pmid">28847797</pub-id></mixed-citation></ref><ref id="wjs12484-bib-0010"><label>10</label><mixed-citation publication-type="journal" id="wjs12484-cit-0010"><string-name name-style="western"><given-names>E.</given-names><surname>Stenberg</surname></string-name> and <string-name name-style="western"><given-names>E.</given-names><surname>N&#228;slund</surname></string-name>, &#8220;<article-title>Major Adverse Cardiovascular Events Among Patients With Type&#8208;2 Diabetes, a Nationwide Cohort Study Comparing Primary Metabolic and Bariatric Surgery to GLP&#8208;1 Receptor Agonist Treatment</article-title>,&#8221; <source>International Journal of Obesity</source><volume>47</volume>, no. <issue>4</issue> (<year>2023</year>): <fpage>251</fpage>&#8211;<lpage>256</lpage>, <pub-id pub-id-type="doi">10.1038/s41366-023-01254-z</pub-id>.<pub-id pub-id-type="pmid">36670155</pub-id><pub-id pub-id-type="pmcid">PMC10113141</pub-id></mixed-citation></ref><ref id="wjs12484-bib-0011"><label>11</label><mixed-citation publication-type="journal" id="wjs12484-cit-0011"><string-name name-style="western"><given-names>J. M.</given-names><surname>Hyer</surname></string-name>, <string-name name-style="western"><given-names>A.</given-names><surname>Ejaz</surname></string-name>, <string-name name-style="western"><given-names>D. I.</given-names><surname>Tsilimigras</surname></string-name>, <string-name name-style="western"><given-names>A. Z.</given-names><surname>Paredes</surname></string-name>, <string-name name-style="western"><given-names>R.</given-names><surname>Mehta</surname></string-name>, and <string-name name-style="western"><given-names>T. M.</given-names><surname>Pawlik</surname></string-name>, &#8220;<article-title>Novel Machine Learning Approach to Identify Preoperative Risk Factors Associated With Super&#8208;Utilization of Medicare Expenditure Following Surgery</article-title>,&#8221; <source>JAMA Surg</source><volume>154</volume>, no. <issue>11</issue> (<year>2019</year>): <elocation-id>1014</elocation-id>, <pub-id pub-id-type="doi">10.1001/jamasurg.2019.2979</pub-id>.<pub-id pub-id-type="pmid">31411664</pub-id><pub-id pub-id-type="pmcid">PMC6694398</pub-id></mixed-citation></ref><ref id="wjs12484-bib-0012"><label>12</label><mixed-citation publication-type="journal" id="wjs12484-cit-0012"><string-name name-style="western"><given-names>Z.</given-names><surname>Bloomgarden</surname></string-name>, &#8220;<article-title>Should Glucagon&#8208;Like Peptide&#8208;1 Receptor Agonist Treatment Be Withheld in Preoperative Management?</article-title>,&#8221; <source>Journal of Diabetes</source><volume>15</volume>, no. <issue>9</issue> (<year>2023</year>): <fpage>712</fpage>&#8211;<lpage>713</lpage>, <pub-id pub-id-type="doi">10.1111/1753-0407.13469</pub-id>.<pub-id pub-id-type="pmid">37727016</pub-id><pub-id pub-id-type="pmcid">PMC10509509</pub-id></mixed-citation></ref><ref id="wjs12484-bib-0013"><label>13</label><mixed-citation publication-type="journal" id="wjs12484-cit-0013"><string-name name-style="western"><given-names>U.</given-names><surname>Galway</surname></string-name>, <string-name name-style="western"><given-names>P.</given-names><surname>Chahar</surname></string-name>, <string-name name-style="western"><given-names>M. T.</given-names><surname>Schmidt</surname></string-name>, et&#160;al. &#8220;<article-title>Perioperative Challenges in Management of Diabetic Patients Undergoing Non&#8208;Cardiac Surgery</article-title>,&#8221; <source>World Journal of Diabetes</source><volume>12</volume>, no. <issue>8</issue> (<year>2021</year>): <fpage>1255</fpage>&#8211;<lpage>1266</lpage>, <pub-id pub-id-type="doi">10.4239/wjd.v12.i8.1255</pub-id>.<pub-id pub-id-type="pmid">34512891</pub-id><pub-id pub-id-type="pmcid">PMC8394235</pub-id></mixed-citation></ref><ref id="wjs12484-bib-0014"><label>14</label><mixed-citation publication-type="miscellaneous" id="wjs12484-cit-0014"><string-name name-style="western"><given-names>G. P.</given-names><surname>Joshi</surname></string-name>, <string-name name-style="western"><given-names>B. B.</given-names><surname>Abdelmalak</surname></string-name>, <string-name name-style="western"><given-names>W. A.</given-names><surname>Weigel</surname></string-name>, et al. <article-title>American Society of Anesthesiologist (ASA) Task Force on Perioperative Fasting: American Society of Anesthesiologists Consensus&#8208;Based Guidance on Preoperative Management of Patients (Adults and Children) on Glucagon&#8208;Like Peptide&#8208;1 (GLP&#8208;1) Receptor Agonists</article-title>. Accessed July 12, <year>2024</year>, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.asahq.org/about-asa/newsroom/news-releases/2023/06/american-society-of-anesthesiologists-consensusbased-guidance-on-preoperative" ext-link-type="uri">https://www.asahq.org/about-asa/newsroom/news-releases/2023/06/american-society-of-anesthesiologists-consensusbased-guidance-on-preoperative</ext-link>.</mixed-citation></ref><ref id="wjs12484-bib-0015"><label>15</label><mixed-citation publication-type="journal" id="wjs12484-cit-0015"><string-name name-style="western"><given-names>M.</given-names><surname>Khalil</surname></string-name>, <string-name name-style="western"><given-names>S.</given-names><surname>Woldesenbet</surname></string-name>, <string-name name-style="western"><given-names>M. M.</given-names><surname>Munir</surname></string-name>, et&#160;al. &#8220;<article-title>Healthcare Utilization and Expenditures Among Patients With Venous Thromboembolism Following Gastrointestinal Cancer Surgery</article-title>,&#8221; <source>Journal of Gastrointestinal Surgery</source><volume>28</volume>, no. <issue>7</issue> (<year>2024</year>): <elocation-id>S1091255X24004517</elocation-id>: Published online, <pub-id pub-id-type="doi">10.1016/j.gassur.2024.05.012</pub-id>.<pub-id pub-id-type="pmid">38762336</pub-id></mixed-citation></ref><ref id="wjs12484-bib-0016"><label>16</label><mixed-citation publication-type="journal" id="wjs12484-cit-0016"><string-name name-style="western"><given-names>Z.</given-names><surname>Rashid</surname></string-name>, <string-name name-style="western"><given-names>S.</given-names><surname>Woldesenbet</surname></string-name>, <string-name name-style="western"><given-names>M. M.</given-names><surname>Munir</surname></string-name>, et&#160;al. &#8220;<article-title>Open Versus Minimally Invasive Surgery: Risk of New Persistent Opioid Use</article-title>,&#8221; <source>Journal of Gastrointestinal Surgery</source><volume>29</volume> (<year>2024</year>): <elocation-id>101873</elocation-id>: Published online October, <pub-id pub-id-type="doi">10.1016/j.gassur.2024.10.028</pub-id>.<pub-id pub-id-type="pmid">39481527</pub-id></mixed-citation></ref><ref id="wjs12484-bib-0017"><label>17</label><mixed-citation publication-type="journal" id="wjs12484-cit-0017"><string-name name-style="western"><given-names>S. S.</given-names><surname>Lansing</surname></string-name>, <string-name name-style="western"><given-names>A.</given-names><surname>Diaz</surname></string-name>, <string-name name-style="western"><given-names>M.</given-names><surname>Hyer</surname></string-name>, <string-name name-style="western"><given-names>D.</given-names><surname>Tsilimigras</surname></string-name>, and <string-name name-style="western"><given-names>T. M.</given-names><surname>Pawlik</surname></string-name>, &#8220;<article-title>Rural Hospitals Are Not Associated With Worse Postoperative Outcomes for Colon Cancer Surgery</article-title>,&#8221; <source>Journal of Rural Health</source><volume>38</volume>, no. <issue>3</issue> (<year>2022</year>): <fpage>650</fpage>&#8211;<lpage>659</lpage>, <pub-id pub-id-type="doi">10.1111/jrh.12596</pub-id>.<pub-id pub-id-type="pmid">34014573</pub-id></mixed-citation></ref><ref id="wjs12484-bib-0018"><label>18</label><mixed-citation publication-type="journal" id="wjs12484-cit-0018"><string-name name-style="western"><given-names>Z.</given-names><surname>Rashid</surname></string-name>, <string-name name-style="western"><given-names>M. M.</given-names><surname>Munir</surname></string-name>, <string-name name-style="western"><given-names>S.</given-names><surname>Woldesenbet</surname></string-name>, et&#160;al. &#8220;<article-title>Association Between Social Determinants of Health and Delayed Postoperative Adjuvant Therapy Among Patients Undergoing Resection of Pancreatic Cancer</article-title>,&#8221; <source>Journal of Surgical Oncology</source><volume>129</volume>, no. <issue>5</issue> (<year>2024</year>): <fpage>850</fpage>&#8211;<lpage>859</lpage>, <pub-id pub-id-type="doi">10.1002/jso.27571</pub-id>.<pub-id pub-id-type="pmid">38151795</pub-id></mixed-citation></ref><ref id="wjs12484-bib-0019"><label>19</label><mixed-citation publication-type="book" id="wjs12484-cit-0019"><string-name name-style="western"><given-names>A. M.</given-names><surname>Butler</surname></string-name>, <string-name name-style="western"><given-names>K. B.</given-names><surname>Nickel</surname></string-name>, <string-name name-style="western"><given-names>R. A.</given-names><surname>Overman</surname></string-name>, and <string-name name-style="western"><given-names>M. A.</given-names><surname>Brookhart</surname></string-name>, &#8220;<part-title>IBM MarketScan Research Databases</part-title>,&#8221; in <source>Databases for Pharmacoepidemiological Research</source>, eds. <person-group person-group-type="editor"><string-name name-style="western"><given-names>M.</given-names><surname>Sturkenboom</surname></string-name></person-group> and <person-group person-group-type="editor"><string-name name-style="western"><given-names>T.</given-names><surname>Schink</surname></string-name></person-group> (<publisher-name>Springer International Publishing</publisher-name>, <year>2021</year>): <fpage>243</fpage>&#8211;<lpage>251</lpage>, <pub-id pub-id-type="doi">10.1007/978-3-030-51455-6_20</pub-id>.</mixed-citation></ref><ref id="wjs12484-bib-0020"><label>20</label><mixed-citation publication-type="journal" id="wjs12484-cit-0020"><string-name name-style="western"><given-names>D. H.</given-names><surname>Kim</surname></string-name>, <string-name name-style="western"><given-names>S.</given-names><surname>Schneeweiss</surname></string-name>, <string-name name-style="western"><given-names>R. J.</given-names><surname>Glynn</surname></string-name>, <string-name name-style="western"><given-names>L. A.</given-names><surname>Lipsitz</surname></string-name>, <string-name name-style="western"><given-names>K.</given-names><surname>Rockwood</surname></string-name>, and <string-name name-style="western"><given-names>J.</given-names><surname>Avorn</surname></string-name>, &#8220;<article-title>Measuring Frailty in Medicare Data: Development and Validation of a Claims&#8208;Based Frailty Index</article-title>,&#8221; <source>J Gerontol A Biol Sci Med Sci</source><volume>73</volume>, no. <issue>7</issue> (<year>2018</year>): <fpage>980</fpage>&#8211;<lpage>987</lpage>, <pub-id pub-id-type="doi">10.1093/gerona/glx229</pub-id>.<pub-id pub-id-type="pmid">29244057</pub-id><pub-id pub-id-type="pmcid">PMC6001883</pub-id></mixed-citation></ref><ref id="wjs12484-bib-0021"><label>21</label><mixed-citation publication-type="journal" id="wjs12484-cit-0021"><string-name name-style="western"><given-names>J. M.</given-names><surname>Hyer</surname></string-name>, <string-name name-style="western"><given-names>D. I.</given-names><surname>Tsilimigras</surname></string-name>, <string-name name-style="western"><given-names>A. Z.</given-names><surname>Paredes</surname></string-name>, <string-name name-style="western"><given-names>K.</given-names><surname>Sahara</surname></string-name>, <string-name name-style="western"><given-names>S.</given-names><surname>White</surname></string-name>, and <string-name name-style="western"><given-names>T. M.</given-names><surname>Pawlik</surname></string-name>, &#8220;<article-title>Is Annual Preoperative Utilization an Indicator of Postoperative Surgical Outcomes? A Study in Medicare Expenditure</article-title>,&#8221; <source>World Journal of Surgery</source><volume>44</volume>, no. <issue>1</issue> (<year>2020</year>): <fpage>108</fpage>&#8211;<lpage>114</lpage>, <pub-id pub-id-type="doi">10.1007/s00268-019-05184-8</pub-id>.<pub-id pub-id-type="pmid">31531723</pub-id></mixed-citation></ref><ref id="wjs12484-bib-0022"><label>22</label><mixed-citation publication-type="journal" id="wjs12484-cit-0022"><string-name name-style="western"><given-names>M.</given-names><surname>Khalil</surname></string-name>, <string-name name-style="western"><given-names>S.</given-names><surname>Woldesenbet</surname></string-name>, <string-name name-style="western"><given-names>M. M.</given-names><surname>Munir</surname></string-name>, et&#160;al. &#8220;<article-title>Long&#8208;Term Health Outcomes of New Persistent Opioid Use After Gastrointestinal Cancer Surgery</article-title>,&#8221; <source>Annals of Surgical Oncology</source><volume>31</volume>, no. <issue>8</issue> (<year>2024</year>): <fpage>5283</fpage>&#8211;<lpage>5292</lpage>: Published online May 18, <pub-id pub-id-type="doi">10.1245/s10434-024-15435-1</pub-id>.<pub-id pub-id-type="pmid">38762641</pub-id><pub-id pub-id-type="pmcid">PMC11236845</pub-id></mixed-citation></ref><ref id="wjs12484-bib-0023"><label>23</label><mixed-citation publication-type="journal" id="wjs12484-cit-0023"><string-name name-style="western"><given-names>M.</given-names><surname>Abdelwahab</surname></string-name>, <string-name name-style="western"><given-names>C. D.</given-names><surname>Lynch</surname></string-name>, <string-name name-style="western"><given-names>P.</given-names><surname>Schneider</surname></string-name>, et&#160;al. &#8220;<article-title>Postoperative Complications After Non&#8208;Obstetric Surgery Among Pregnant Patients in the National Surgical Quality Improvement Program, 2005&#8211;2012</article-title>,&#8221; <source>American Journal of Surgery</source><volume>223</volume>, no. <issue>2</issue> (<year>2022</year>): <fpage>364</fpage>&#8211;<lpage>369</lpage>, <pub-id pub-id-type="doi">10.1016/j.amjsurg.2021.04.002</pub-id>.<pub-id pub-id-type="pmid">33865564</pub-id></mixed-citation></ref><ref id="wjs12484-bib-0024"><label>24</label><mixed-citation publication-type="journal" id="wjs12484-cit-0024"><string-name name-style="western"><given-names>Z.</given-names><surname>Rashid</surname></string-name>, <string-name name-style="western"><given-names>M. M.</given-names><surname>Munir</surname></string-name>, <string-name name-style="western"><given-names>S.</given-names><surname>Woldesenbet</surname></string-name>, et&#160;al. &#8220;<article-title>Association of Preoperative Cholangitis With Outcomes and Expenditures Among Patients Undergoing Pancreaticoduodenectomy</article-title>,&#8221; <source>Journal of Gastrointestinal Surgery</source><volume>18</volume>, no. <issue>7</issue> (<year>2024</year>): <fpage>1137</fpage>&#8211;<lpage>1144</lpage>: Published online May, <pub-id pub-id-type="doi">10.1016/j.gassur.2024.05.009</pub-id>.<pub-id pub-id-type="pmid">38762337</pub-id></mixed-citation></ref><ref id="wjs12484-bib-0025"><label>25</label><mixed-citation publication-type="journal" id="wjs12484-cit-0025"><string-name name-style="western"><given-names>G.</given-names><surname>Spolverato</surname></string-name>, <string-name name-style="western"><given-names>A.</given-names><surname>Ejaz</surname></string-name>, <string-name name-style="western"><given-names>O.</given-names><surname>Hyder</surname></string-name>, <string-name name-style="western"><given-names>Y.</given-names><surname>Kim</surname></string-name>, and <string-name name-style="western"><given-names>T. M.</given-names><surname>Pawlik</surname></string-name>, &#8220;<article-title>Failure to Rescue as a Source of Variation in Hospital Mortality After Hepatic Surgery</article-title>,&#8221; <source>British Journal of Surgery</source><volume>101</volume>, no. <issue>7</issue> (<year>2014</year>): <fpage>836</fpage>&#8211;<lpage>846</lpage>, <pub-id pub-id-type="doi">10.1002/bjs.9492</pub-id>.<pub-id pub-id-type="pmid">24760705</pub-id></mixed-citation></ref><ref id="wjs12484-bib-0026"><label>26</label><mixed-citation publication-type="journal" id="wjs12484-cit-0026"><string-name name-style="western"><given-names>S.</given-names><surname>Sen</surname></string-name>, <string-name name-style="western"><given-names>P. P.</given-names><surname>Potnuru</surname></string-name>, <string-name name-style="western"><given-names>N.</given-names><surname>Hernandez</surname></string-name>, et&#160;al. &#8220;<article-title>Glucagon&#8208;Like Peptide&#8208;1 Receptor Agonist Use and Residual Gastric Content Before Anesthesia</article-title>,&#8221; <source>JAMA Surgery</source><volume>159</volume>, no. <issue>6</issue> (<year>2024</year>): <fpage>660</fpage>&#8211;<lpage>667</lpage>, <pub-id pub-id-type="doi">10.1001/jamasurg.2024.0111</pub-id>.<pub-id pub-id-type="pmid">38446466</pub-id><pub-id pub-id-type="pmcid">PMC10918573</pub-id></mixed-citation></ref><ref id="wjs12484-bib-0027"><label>27</label><mixed-citation publication-type="journal" id="wjs12484-cit-0027"><string-name name-style="western"><given-names>L. S.</given-names><surname>Tao</surname></string-name>, <string-name name-style="western"><given-names>C. R.</given-names><surname>MacKenzie</surname></string-name>, and <string-name name-style="western"><given-names>M. E.</given-names><surname>Charlson</surname></string-name>, &#8220;<article-title>Predictors of Postoperative Complications in the Patient With Diabetes Mellitus</article-title>,&#8221; <source>Journal of Diabetes and its Complications</source><volume>22</volume>, no. <issue>1</issue> (<year>2008</year>): <fpage>24</fpage>&#8211;<lpage>28</lpage>, <pub-id pub-id-type="doi">10.1016/j.jdiacomp.2007.05.008</pub-id>.<pub-id pub-id-type="pmid">18191074</pub-id></mixed-citation></ref><ref id="wjs12484-bib-0028"><label>28</label><mixed-citation publication-type="journal" id="wjs12484-cit-0028"><string-name name-style="western"><given-names>Z.</given-names><surname>Rashid</surname></string-name>, <string-name name-style="western"><given-names>M.</given-names><surname>Khalil</surname></string-name>, <string-name name-style="western"><given-names>M. M. M.</given-names><surname>Khan</surname></string-name>, et&#160;al. &#8220;<article-title>Upper Gastrointestinal Cancers: Trends and Determinants of Location of Death</article-title>,&#8221; <source>Surgery</source><volume>19</volume> (<year>2024</year>): <elocation-id>108797</elocation-id>: Published online September, <pub-id pub-id-type="doi">10.1016/j.surg.2024.06.056</pub-id>.<pub-id pub-id-type="pmid">39299855</pub-id></mixed-citation></ref><ref id="wjs12484-bib-0029"><label>29</label><mixed-citation publication-type="journal" id="wjs12484-cit-0029"><string-name name-style="western"><given-names>M. J.</given-names><surname>Grosso</surname></string-name>, <string-name name-style="western"><given-names>A. L.</given-names><surname>Neuwirth</surname></string-name>, <string-name name-style="western"><given-names>V.</given-names><surname>Boddapati</surname></string-name>, <string-name name-style="western"><given-names>R. P.</given-names><surname>Shah</surname></string-name>, <string-name name-style="western"><given-names>H. J.</given-names><surname>Cooper</surname></string-name>, and <string-name name-style="western"><given-names>J. A.</given-names><surname>Geller</surname></string-name>, &#8220;<article-title>Decreasing Length of Hospital Stay and Postoperative Complications After Primary Total Hip Arthroplasty: A Decade Analysis From 2006 to 2016</article-title>,&#8221; <source>Journal of Arthroplasty</source><volume>34</volume>, no. <issue>3</issue> (<year>2019</year>): <fpage>422</fpage>&#8211;<lpage>425</lpage>, <pub-id pub-id-type="doi">10.1016/j.arth.2018.11.005</pub-id>.<pub-id pub-id-type="pmid">30503306</pub-id></mixed-citation></ref><ref id="wjs12484-bib-0030"><label>30</label><mixed-citation publication-type="journal" id="wjs12484-cit-0030"><string-name name-style="western"><given-names>B. T.</given-names><surname>Fry</surname></string-name>, <string-name name-style="western"><given-names>M. E.</given-names><surname>Smith</surname></string-name>, <string-name name-style="western"><given-names>J. R.</given-names><surname>Thumma</surname></string-name>, <string-name name-style="western"><given-names>A. A.</given-names><surname>Ghaferi</surname></string-name>, and <string-name name-style="western"><given-names>J. B.</given-names><surname>Dimick</surname></string-name>, &#8220;<article-title>Ten&#8208;Year Trends in Surgical Mortality, Complications, and Failure to Rescue in Medicare Beneficiaries</article-title>,&#8221; <source>Annals of Surgery</source><volume>271</volume>, no. <issue>5</issue> (<year>2020</year>): <fpage>855</fpage>&#8211;<lpage>861</lpage>, <pub-id pub-id-type="doi">10.1097/SLA.0000000000003193</pub-id>.<pub-id pub-id-type="pmid">31306158</pub-id></mixed-citation></ref><ref id="wjs12484-bib-0031"><label>31</label><mixed-citation publication-type="journal" id="wjs12484-cit-0031"><string-name name-style="western"><given-names>K.</given-names><surname>Merath</surname></string-name>, <string-name name-style="western"><given-names>J. M.</given-names><surname>Hyer</surname></string-name>, <string-name name-style="western"><given-names>R.</given-names><surname>Mehta</surname></string-name>, et&#160;al. &#8220;<article-title>Use of Machine Learning for Prediction of Patient Risk of Postoperative Complications After Liver, Pancreatic, and Colorectal Surgery</article-title>,&#8221; <source>Journal of Gastrointestinal Surgery</source><volume>24</volume>, no. <issue>8</issue> (<year>2020</year>): <fpage>1843</fpage>&#8211;<lpage>1851</lpage>, <pub-id pub-id-type="doi">10.1007/s11605-019-04338-2</pub-id>.<pub-id pub-id-type="pmid">31385172</pub-id></mixed-citation></ref><ref id="wjs12484-bib-0032"><label>32</label><mixed-citation publication-type="journal" id="wjs12484-cit-0032"><string-name name-style="western"><given-names>A.</given-names><surname>Paro</surname></string-name>, <string-name name-style="western"><given-names>D.</given-names><surname>Dalmacy</surname></string-name>, <string-name name-style="western"><given-names>J. M.</given-names><surname>Hyer</surname></string-name>, <string-name name-style="western"><given-names>D. I.</given-names><surname>Tsilimigras</surname></string-name>, <string-name name-style="western"><given-names>A.</given-names><surname>Diaz</surname></string-name>, and <string-name name-style="western"><given-names>T. M.</given-names><surname>Pawlik</surname></string-name>, &#8220;<article-title>Impact of Perioperative Thromboembolic Complications on Future Long&#8208;Term Risk of Venous Thromboembolism Among Medicare Beneficiaries Undergoing Complex Gastrointestinal Surgery</article-title>,&#8221; <source>Journal of Gastrointestinal Surgery</source><volume>25</volume>, no. <issue>12</issue> (<year>2021</year>): <fpage>3064</fpage>&#8211;<lpage>3073</lpage>, <pub-id pub-id-type="doi">10.1007/s11605-021-05080-4</pub-id>.<pub-id pub-id-type="pmid">34282525</pub-id></mixed-citation></ref><ref id="wjs12484-bib-0033"><label>33</label><mixed-citation publication-type="journal" id="wjs12484-cit-0033"><string-name name-style="western"><given-names>Z.</given-names><surname>Rashid</surname></string-name>, <string-name name-style="western"><given-names>M. M.</given-names><surname>Munir</surname></string-name>, <string-name name-style="western"><given-names>S.</given-names><surname>Woldesenbet</surname></string-name>, et&#160;al. &#8220;<article-title>Care Fragmentation in Hepatopancreatic Surgery and Postoperative Outcomes</article-title>,&#8221; <source>Surgery</source><volume>175</volume>, no. <issue>6</issue> (<year>2024</year>): <fpage>1562</fpage>&#8211;<lpage>1569</lpage>: Published online April 1, <pub-id pub-id-type="doi">10.1016/j.surg.2024.02.021</pub-id>.<pub-id pub-id-type="pmid">38565495</pub-id></mixed-citation></ref><ref id="wjs12484-bib-0034"><label>34</label><mixed-citation publication-type="journal" id="wjs12484-cit-0034"><string-name name-style="western"><given-names>I. B.</given-names><surname>Hirsch</surname></string-name>, &#8220;<article-title>The Future of the GLP&#8208;1 Receptor Agonists</article-title>,&#8221; <source>JAMA</source><volume>321</volume>, no. <issue>15</issue> (<year>2019</year>): <fpage>1457</fpage>&#8211;<lpage>1458</lpage>, <pub-id pub-id-type="doi">10.1001/jama.2019.2941</pub-id>.<pub-id pub-id-type="pmid">30903797</pub-id></mixed-citation></ref><ref id="wjs12484-bib-0035"><label>35</label><mixed-citation publication-type="journal" id="wjs12484-cit-0035"><string-name name-style="western"><given-names>H.</given-names><surname>Hausner</surname></string-name>, <string-name name-style="western"><given-names>J.</given-names><surname>Derving Karsb&#248;l</surname></string-name>, <string-name name-style="western"><given-names>A. G.</given-names><surname>Holst</surname></string-name>, et&#160;al. &#8220;<article-title>Effect of Semaglutide on the Pharmacokinetics of Metformin, Warfarin, Atorvastatin and Digoxin in Healthy Subjects</article-title>,&#8221; <source>Clinical Pharmacokinetics</source><volume>56</volume>, no. <issue>11</issue> (<year>2017</year>): <fpage>1391</fpage>&#8211;<lpage>1401</lpage>, <pub-id pub-id-type="doi">10.1007/s40262-017-0532-6</pub-id>.<pub-id pub-id-type="pmid">28349387</pub-id><pub-id pub-id-type="pmcid">PMC5648738</pub-id></mixed-citation></ref><ref id="wjs12484-bib-0036"><label>36</label><mixed-citation publication-type="journal" id="wjs12484-cit-0036"><string-name name-style="western"><given-names>L.</given-names><surname>Liu</surname></string-name>, <string-name name-style="western"><given-names>J.</given-names><surname>Chen</surname></string-name>, <string-name name-style="western"><given-names>L.</given-names><surname>Wang</surname></string-name>, <string-name name-style="western"><given-names>C.</given-names><surname>Chen</surname></string-name>, and <string-name name-style="western"><given-names>Li</given-names><surname>Chen</surname></string-name>, &#8220;<article-title>Association Between Different GLP&#8208;1 Receptor Agonists and Gastrointestinal Adverse Reactions: A Real&#8208;World Disproportionality Study Based on FDA Adverse Event Reporting System Database</article-title>,&#8221; <source>Frontiers in Endocrinology</source><volume>13</volume> (<year>2022</year>), <pub-id pub-id-type="doi">10.3389/fendo.2022.1043789</pub-id>.<pub-id pub-id-type="pmcid">PMC9770009</pub-id><pub-id pub-id-type="pmid">36568085</pub-id></mixed-citation></ref><ref id="wjs12484-bib-0037"><label>37</label><mixed-citation publication-type="journal" id="wjs12484-cit-0037"><string-name name-style="western"><given-names>J.</given-names><surname>Wan</surname></string-name>, <string-name name-style="western"><given-names>C.</given-names><surname>Ferrari</surname></string-name>, and <string-name name-style="western"><given-names>M.</given-names><surname>Tadros</surname></string-name>, &#8220;<article-title>GLP&#8208;1RA Essentials in Gastroenterology: Side Effect Management, Precautions for Endoscopy and Applications for Gastrointestinal Disease Treatment</article-title>,&#8221; <source>Gastroenterology Insights</source><volume>15</volume>, no. <issue>1</issue> (<year>2024</year>): <fpage>191</fpage>&#8211;<lpage>212</lpage>, <pub-id pub-id-type="doi">10.3390/gastroent15010014</pub-id>.</mixed-citation></ref><ref id="wjs12484-bib-0038"><label>38</label><mixed-citation publication-type="journal" id="wjs12484-cit-0038"><string-name name-style="western"><given-names>P. M.</given-names><surname>Jones</surname></string-name>, <string-name name-style="western"><given-names>I. A.</given-names><surname>Hobai</surname></string-name>, and <string-name name-style="western"><given-names>P. M.</given-names><surname>Murphy</surname></string-name>, &#8220;<article-title>Anesthesia and Glucagon&#8208;Like Peptide&#8208;1 Receptor Agonists: Proceed With Caution</article-title>,&#8221; <source>Can J Anesth/J Can Anesth</source><volume>70</volume>, no. <issue>8</issue> (<year>2023</year>): <fpage>1281</fpage>&#8211;<lpage>1286</lpage>, <pub-id pub-id-type="doi">10.1007/s12630-023-02550-y</pub-id>.<pub-id pub-id-type="pmid">37466910</pub-id></mixed-citation></ref><ref id="wjs12484-bib-0039"><label>39</label><mixed-citation publication-type="journal" id="wjs12484-cit-0039"><string-name name-style="western"><given-names>Y. H.</given-names><surname>Yeo</surname></string-name>, <string-name name-style="western"><given-names>S.</given-names><surname>Gaddam</surname></string-name>, <string-name name-style="western"><given-names>W. H.</given-names><surname>Ng</surname></string-name>, et&#160;al. &#8220;<article-title>Increased Risk of Aspiration Pneumonia Associated With Endoscopic Procedures Among Patients With Glucagon&#8208;Like Peptide 1 Receptor Agonist Use</article-title>,&#8221; <source>Gastroenterology</source><volume>167</volume>, no. <issue>2</issue> (<year>2024</year>): <fpage>402</fpage>&#8211;<lpage>404.e3</lpage>, <pub-id pub-id-type="doi">10.1053/j.gastro.2024.03.015</pub-id>.<pub-id pub-id-type="pmid">38552724</pub-id></mixed-citation></ref><ref id="wjs12484-bib-0040"><label>40</label><mixed-citation publication-type="journal" id="wjs12484-cit-0040"><string-name name-style="western"><given-names>G.</given-names><surname>Jia</surname></string-name>, <string-name name-style="western"><given-names>A. R.</given-names><surname>Aroor</surname></string-name>, and <string-name name-style="western"><given-names>J. R.</given-names><surname>Sowers</surname></string-name>, &#8220;<article-title>Glucagon&#8208;Like Peptide 1 Receptor Activation and Platelet Function: Beyond Glycemic Control</article-title>,&#8221; <source>Diabetes</source><volume>65</volume>, no. <issue>6</issue> (<year>2016</year>): <fpage>1487</fpage>&#8211;<lpage>1489</lpage>, <pub-id pub-id-type="doi">10.2337/dbi16-0014</pub-id>.<pub-id pub-id-type="pmid">27222394</pub-id><pub-id pub-id-type="pmcid">PMC4878428</pub-id></mixed-citation></ref><ref id="wjs12484-bib-0041"><label>41</label><mixed-citation publication-type="journal" id="wjs12484-cit-0041"><string-name name-style="western"><given-names>K. N.</given-names><surname>Cahill</surname></string-name>, <string-name name-style="western"><given-names>T.</given-names><surname>Amin</surname></string-name>, <string-name name-style="western"><given-names>O.</given-names><surname>Boutaud</surname></string-name>, et&#160;al. &#8220;<article-title>Glucagon&#8208;Like Peptide&#8208;1 Receptor Regulates Thromboxane&#8208;Induced Human Platelet Activation</article-title>,&#8221; <source>Journal of the American College of Cardiology: Basic to Translational Science</source><volume>7</volume>, no. <issue>7</issue> (<year>2022</year>): <fpage>713</fpage>&#8211;<lpage>715</lpage>, <pub-id pub-id-type="doi">10.1016/j.jacbts.2022.04.004</pub-id>.<pub-id pub-id-type="pmid">35958685</pub-id><pub-id pub-id-type="pmcid">PMC9357570</pub-id></mixed-citation></ref><ref id="wjs12484-bib-0042"><label>42</label><mixed-citation publication-type="journal" id="wjs12484-cit-0042"><string-name name-style="western"><given-names>A.</given-names><surname>Ata</surname></string-name>, <string-name name-style="western"><given-names>J.</given-names><surname>Lee</surname></string-name>, <string-name name-style="western"><given-names>S. L.</given-names><surname>Bestle</surname></string-name>, <string-name name-style="western"><given-names>J.</given-names><surname>Desemone</surname></string-name>, and <string-name name-style="western"><given-names>S. C.</given-names><surname>Stain</surname></string-name>, &#8220;<article-title>Postoperative Hyperglycemia and Surgical Site Infection in General Surgery Patients</article-title>,&#8221; <source>Archives of Surgery</source><volume>145</volume>, no. <issue>9</issue> (<year>2010</year>): <fpage>858</fpage>&#8211;<lpage>864</lpage>, <pub-id pub-id-type="doi">10.1001/archsurg.2010.179</pub-id>.<pub-id pub-id-type="pmid">20855756</pub-id></mixed-citation></ref><ref id="wjs12484-bib-0043"><label>43</label><mixed-citation publication-type="journal" id="wjs12484-cit-0043"><string-name name-style="western"><given-names>S. E.</given-names><surname>Capes</surname></string-name>, <string-name name-style="western"><given-names>D.</given-names><surname>Hunt</surname></string-name>, <string-name name-style="western"><given-names>K.</given-names><surname>Malmberg</surname></string-name>, and <string-name name-style="western"><given-names>H. C.</given-names><surname>Gerstein</surname></string-name>, &#8220;<article-title>Stress Hyperglycaemia and Increased Risk of Death After Myocardial Infarction in Patients With and Without Diabetes: A Systematic Overview</article-title>,&#8221; <source>Lancet</source><volume>355</volume>, no. <issue>9206</issue> (<year>2000</year>): <fpage>773</fpage>&#8211;<lpage>778</lpage>, <pub-id pub-id-type="doi">10.1016/S0140-6736(99)08415-9</pub-id>.<pub-id pub-id-type="pmid">10711923</pub-id></mixed-citation></ref><ref id="wjs12484-bib-0044"><label>44</label><mixed-citation publication-type="journal" id="wjs12484-cit-0044"><collab collab-type="authors">National Nosocomial Infections Surveillance (NNIS) System Report</collab>
, &#8220;<article-title>Data Summary From January 1992&#8208;June 2001, Issued August 2001</article-title>,&#8221; <source>American Journal of Infection Control</source><volume>29</volume>, no. <issue>6</issue> (<year>2001</year>): <fpage>404</fpage>&#8211;<lpage>421</lpage>, <pub-id pub-id-type="doi">10.1067/mic.2001.119952</pub-id>.<pub-id pub-id-type="pmid">11743489</pub-id></mixed-citation></ref><ref id="wjs12484-bib-0045"><label>45</label><mixed-citation publication-type="journal" id="wjs12484-cit-0045"><string-name name-style="western"><given-names>M.</given-names><surname>Zapf</surname></string-name>, <string-name name-style="western"><given-names>D.</given-names><surname>Patel</surname></string-name>, <string-name name-style="western"><given-names>P.</given-names><surname>Henson</surname></string-name>, et&#160;al. &#8220;<article-title>PeRiOperative Glucose PRAgMatic (PROGRAM) Trial Protocol and Statistical Analysis Plan for Comparing Automated Intraoperative Reminders to Standardise Insulin Administration in Surgical Patients at High Risk of Hyperglycaemia</article-title>,&#8221; <source>BMJ Open</source><volume>13</volume>, no. <issue>8</issue> (<year>2023</year>): <elocation-id>e072745</elocation-id>, <pub-id pub-id-type="doi">10.1136/bmjopen-2023-072745</pub-id>.<pub-id pub-id-type="pmcid">PMC10450072</pub-id><pub-id pub-id-type="pmid">37620270</pub-id></mixed-citation></ref><ref id="wjs12484-bib-0046"><label>46</label><mixed-citation publication-type="journal" id="wjs12484-cit-0046"><string-name name-style="western"><given-names>T.</given-names><surname>Liu</surname></string-name>, <string-name name-style="western"><given-names>L.</given-names><surname>Zhou</surname></string-name>, <string-name name-style="western"><given-names>Y.</given-names><surname>Chen</surname></string-name>, <string-name name-style="western"><given-names>J.</given-names><surname>Lin</surname></string-name>, and <string-name name-style="western"><given-names>H.</given-names><surname>Zhu</surname></string-name>, &#8220;<article-title>Semaglutide Outperforms Insulin in Restoring Neutrophil Function Against Implant&#8208;Related Infection in Diabetic and Obese Mice: Experimental Research</article-title>,&#8221; <source>International Journal of Surgery</source> (<year>2024</year>), <pub-id pub-id-type="doi">10.1097/JS9.0000000000001896</pub-id>.<pub-id pub-id-type="pmcid">PMC11745711</pub-id><pub-id pub-id-type="pmid">38935106</pub-id></mixed-citation></ref><ref id="wjs12484-bib-0047"><label>47</label><mixed-citation publication-type="journal" id="wjs12484-cit-0047"><string-name name-style="western"><given-names>M.</given-names><surname>Jannati</surname></string-name>, &#8220;<article-title>The Value of Prophylactic Antibiotics in Coronary Artery Bypass Graft Surgery: A Review of Literature</article-title>,&#8221; <source>Journal of Vascular Nursing</source><volume>39</volume>, no. <issue>4</issue> (<year>2021</year>): <fpage>100</fpage>&#8211;<lpage>103</lpage>, <pub-id pub-id-type="doi">10.1016/j.jvn.2021.07.005</pub-id>.<pub-id pub-id-type="pmid">34865718</pub-id></mixed-citation></ref><ref id="wjs12484-bib-0048"><label>48</label><mixed-citation publication-type="journal" id="wjs12484-cit-0048"><string-name name-style="western"><given-names>K. A.</given-names><surname>Fisher</surname></string-name>, <string-name name-style="western"><given-names>A. S. L.</given-names><surname>Tan</surname></string-name>, <string-name name-style="western"><given-names>D. D.</given-names><surname>Matlock</surname></string-name>, <string-name name-style="western"><given-names>B.</given-names><surname>Saver</surname></string-name>, <string-name name-style="western"><given-names>K. M.</given-names><surname>Mazor</surname></string-name>, and <string-name name-style="western"><given-names>A. H.</given-names><surname>Pieterse</surname></string-name>, &#8220;<article-title>Keeping the Patient in the Center of Decision Making: Common Challenges in the Practice of Shared Decision Making</article-title>,&#8221; <source>Patient Education and Counseling</source><volume>101</volume>, no. <issue>12</issue> (<year>2018</year>): <fpage>2195</fpage>&#8211;<lpage>2201</lpage>, <pub-id pub-id-type="doi">10.1016/j.pec.2018.08.007</pub-id>.<pub-id pub-id-type="pmid">30144968</pub-id><pub-id pub-id-type="pmcid">PMC6376968</pub-id></mixed-citation></ref><ref id="wjs12484-bib-0049"><label>49</label><mixed-citation publication-type="journal" id="wjs12484-cit-0049"><string-name name-style="western"><given-names>C. M.</given-names><surname>Smith</surname></string-name>, &#8220;<article-title>Origin and Uses of Primum Non Nocere&#8212;Above All, Do No Harm</article-title>,&#8221; <source>Journal of Clinical Pharmacology</source><volume>45</volume>, no. <issue>4</issue> (<year>2005</year>): <fpage>371</fpage>&#8211;<lpage>377</lpage>, <pub-id pub-id-type="doi">10.1177/0091270004273680</pub-id>.<pub-id pub-id-type="pmid">15778417</pub-id></mixed-citation></ref><ref id="wjs12484-bib-0050"><label>50</label><mixed-citation publication-type="journal" id="wjs12484-cit-0050"><string-name name-style="western"><given-names>M.</given-names><surname>Khalil</surname></string-name>, <string-name name-style="western"><given-names>S.</given-names><surname>Woldesenbet</surname></string-name>, <string-name name-style="western"><given-names>M. M.</given-names><surname>Munir</surname></string-name>, et&#160;al. &#8220;<article-title>Surgical Outcomes and Healthcare Expenditures Among Patients With Dementia Undergoing Major Surgery</article-title>,&#8221; <source>World Journal of Surgery</source><volume>48</volume>, no. <issue>5</issue> (<year>2024</year>): <fpage>1075</fpage>&#8211;<lpage>1083</lpage>, <pub-id pub-id-type="doi">10.1002/wjs.12106</pub-id>.<pub-id pub-id-type="pmid">38436547</pub-id></mixed-citation></ref><ref id="wjs12484-bib-0051"><label>51</label><mixed-citation publication-type="journal" id="wjs12484-cit-0051"><string-name name-style="western"><given-names>Z.</given-names><surname>Rashid</surname></string-name>, <string-name name-style="western"><given-names>S.</given-names><surname>Woldesenbet</surname></string-name>, <string-name name-style="western"><given-names>M.</given-names><surname>Khalil</surname></string-name>, et&#160;al. &#8220;<article-title>Impact of GLP&#8208;1RA on the Risk of Adverse Liver Outcomes Among Patients With Alcohol&#8208;Associated Liver Disease and Type 2 Diabetes</article-title>,&#8221; <source>Liver International</source> (<year>2024</year>): Published online October 15, <pub-id pub-id-type="doi">10.1111/liv.16132</pub-id>.<pub-id pub-id-type="pmcid">PMC11892336</pub-id><pub-id pub-id-type="pmid">39403816</pub-id></mixed-citation></ref><ref id="wjs12484-bib-0052"><label>52</label><mixed-citation publication-type="journal" id="wjs12484-cit-0052"><string-name name-style="western"><given-names>Y.</given-names><surname>Endo</surname></string-name>, <string-name name-style="western"><given-names>S.</given-names><surname>Woldesenbet</surname></string-name>, <string-name name-style="western"><given-names>D. I.</given-names><surname>Tsilimigras</surname></string-name>, et&#160;al. &#8220;<article-title>Effect of Telemedicine Use on Medical Spending and Health Care Utilization Among Patients With Gastrointestinal Cancer</article-title>,&#8221; <source>Journal of Gastrointestinal Surgery</source><volume>28</volume>, no. <issue>9</issue> (<year>2024</year>): <fpage>1456</fpage>&#8211;<lpage>1462</lpage>: Published online, <pub-id pub-id-type="doi">10.1016/j.gassur.2024.06.009</pub-id>.<pub-id pub-id-type="pmid">38901553</pub-id></mixed-citation></ref></ref-list></back></article></pmc-articleset>